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ABSTRACT 
Cancer recurrence remains a major concern for cancer patients despite the significant 
advancement in cancer treatment. Cell cycle re-entry of quiescent cancer cells has been 
implicated as a key factor for cancer recurrence. The slow progression of prostate cancer allows 
a window of opportunity for intervention through diet. Therefore, the aim of this thesis was to 
evaluate the potential use of citrus peel extract in halting the cell cycle re-entry of quiescent 
prostate cancer cells.  
Firstly, water extract and hexane extract of citrus peel were prepared using a maceration 
technique. The anticancer activity of the extracts was evaluated on prostate cancer PC-3 and 
LNCaP cells using in-vitro assays. The cell viability analysis showed that hexane extract was 
more effective in reducing cell viability compared to water extract in both cell lines. For cell 
cycle analysis, quiescent prostate cancer PC-3 and LNCAP cells were released to re-enter cell 
cycle in the presence of extract. Water extract completely inhibited the entry of quiescent cells 
from G0/G1 phase to S phase upon release from quiescence. In contrast, the hexane extract 
completely allowed the cells progress to S and G2/M phase. However, both extracts significantly 
decreased the DNA synthesis rate in PC-3 cells compared to the control when analysed using 
EdU incorporation assay. Hesperidin and naringin, the predominant flavonoid compounds in 
water extract, exhibited negligible cell cycle re-entry inhibitory effect on quiescent PC-3 cells 
suggesting the contribution of other bioactive compounds in the extract. More importantly, the 
water extract showed no toxicity when tested on the normal human fibroblast cells. 
Subsequently, solvent extraction and chromatography techniques were used to identify the 
compounds in water extract that are responsible for the cell cycle re-entry inhibitory effect. The 
results showed that the water fraction exhibited the highest inhibitory effect among the fractions 
tested. Not only that, the inhibitory activity of fractions was lower than the water extract 
suggesting the compounds exhibited a greater effect in combination and the presence of a 
synergic effect. Using various analytical methods, citric acid was identified as one of the cell 
cycle re-entry inhibitor compounds present in water extract. The cell viability assay showed the 
IC50 of citric acid for prostate cancer PC-3 cells and normal epithelial prostate RWPE-1 cells 
were almost similar. However, citric acid significantly exhibited higher cell toxicity effect on 
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PC-3 cells than RWPE-1 cells at a concentration above 1 mg/mL indicating the specific toxicity 
of citric acid on cancer cells. Not only that, the citric acid showed no significant toxicity effect 
on human normal fibroblast GM3348 cells when tested on similar concentration.    
As the mechanisms of cell cycle re-entry of quiescent cells remain largely unclear, a study was 
attempted to elucidate the protein changes by the citric acid at the cellular level. The proteomic 
experiment results revealed several proteins were regulated differently in the citric acid treated 
cells that were possible to act with the inhibition of cell cycle re-entry. The Ingenuity Pathway 
Analysis software predicted that citric acid possibly inhibited PC-3 cells from re-entering cell 
cycle mainly by suppressing PI3K/AKT and ERK/MAPK signalling pathways and activating 
PTEN pathway. Modulation of these signalling pathways by diet or drug has the potential to 
reduce the cell cycle re-entry of quiescent prostate cancer cells and preventing cancer recurrence.  
The outcomes of this study have widened the applications of citrus peel extract as a 
chemopreventive agent for post-therapy cancer patients. The recovery and utilization of bioactive 
compounds from citrus peel not only reduce the waste but also will open an avenue for the 
development of affordable fortifying food products with potential in reducing the risk of cancer 
recurrence.   
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1 Introduction 
Cancer recurrence remains a major issue in post-therapy cancer patients. It is defined as the 
return of cancerous cell after a period of time  (Páez, Labonte et al. 2012). The remaining cancer 
cells after the treatment cause cancer recurrence with a high chance of mortality (Rochat 2009, 
Feitelson, Arzumanyan et al. 2015). Thus, practising a healthy lifestyle with regular monitoring 
is vital for cancer patients to reduce the risk of cancer recurrence. Many epidemiological studies 
have shown a positive correlation between high intake of fruits and vegetables with a low 
occurrence of cancer (Block, Patterson et al. 1992, Steinmetz and Potter 1996, Key 2010, 
Rodriguez-Casado 2016). These findings are also in agreement with many in-vitro and in-vivo 
studies, which showed fruits or vegetables and their extracts possesses anticancer activity. Fruits 
and vegetables have the capability in preventing initiation, promotion and progression of cancer. 
However, the ability of fruits and vegetable in preventing cancer recurrence is still unclear and 
not comprehensively studied.  
Citrus is consumed widely and is a source of nutrients with a broad range of health benefit 
including anti-cancer activity (Aggarwal and Shishodia 2006, Meeran, Ahmed et al. 2010, 
Mehta, Murillo et al. 2010). Epidemiological studies showed high intake of citrus and its derived 
products are associated with lower risk of developing various cancer including esophageal, 
gastric, stomach, breast, prostate and pancreas cancer (Ferrís-Tortajada, Berbel-Tornero et al. 
2012, Giacosa, Barale et al. 2013, Cirmi, Ferlazzo et al. 2016, Capurso and Vendemiale 2017). 
The anticancer activity in citrus is contributed by a range of bioactive compounds such as 
flavonoids, limonoids, coumarins, phenolic acids, terpenoids, and carotenoids together with 
many other unknown bioactive components (Yu, Wang et al. 2005, Aggarwal and Shishodia 
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2006, Meeran, Ahmed et al. 2010, Mehta, Murillo et al. 2010, Zou, Xi et al. 2016). A number of 
in-vitro and in-vivo studies have shown the potential anticancer activity of citrus and its derived 
bioactive compounds in inhibiting different cancer lines by modulating various biological events 
leading to anti-proliferation, cell cycle arrest, apoptosis induction, anti-inflammatory, anti-
angiogenesis and anti-metastatic activities (Cirmi, Ferlazzo et al. 2016, Cirmi, Maugeri et al. 
2017). The citrus particularly showed a strong anticancer effect in prostate cancer by inhibiting 
the tumour growth completely in an in-vivo mouse model (Lai, Li et al. 2013b, Kim, Lee et al. 
2017). 
Prostate cancer is one of the leading causes of cancer-related deaths in men. About 1.1 million 
men were diagnosed worldwide with prostate cancer with 307,000 deaths in 2012 (Ferlay, 
Soerjomataram et al. 2015). Despite a significant improvement in 5-year relative survival rate up 
to 95% (AIHW 2017), prostate cancer recurrence remains a major problem in prostate cancer 
patients as up to 50% of the men will experience cancer recurrence within ten years after initial 
surgery (Amling, Blute et al. 2000, Hull, Rabbani et al. 2002, Roehl, Han et al. 2004). Moreover, 
cancer recurrence possesses high mortality threat amongst these patients.  
Although the causes for cancer recurrence are still poorly elucidated, cell cycle re-entry of 
quiescent cancer cells has been suggested for cancer recurrence (Holmgren, O'Reilly et al. 1995). 
There are a complex series of molecular and biochemical signalling pathways that control the 
cell cycle progression. Alteration in the protein expression related to cell cycle by the bioactive 
compound(s) could halt the cell-cycle re-entry. Citrus and its derived bioactive compounds have 
been shown to arrest cell cycle progression in many cancer cell lines such as in breast, colon, 
prostate and lung cells (Cirmi, Ferlazzo et al. 2016). This finding shows the possibility of the 
bioactive compound derived from citrus to arrest the quiescent cancer cells, halt the re-entry into 
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the cell cycle and subsequently delay the prostate cancer recurrence. In fact, anticancer drugs act 
by a variety of mechanisms including by halting the cancer cells from progressing into and in the 
cell cycle. 
Citrus is mainly consumed as juice. Citrus juice industry generates citrus peel, sacs and seed as 
waste products, which account for more than 50% of original fruit weight  (Marín, Soler-Rivas et 
al. 2007). These waste products contain a high amount of different bioactive compounds than the 
juice itself (Miyake, Murakami et al. 1999, Wang, Chuang et al. 2008, Zhang, Wu et al. 2014). 
The bioactive compounds in these waste products can be used as a precursor for the production 
of high-valuable products with emerging applications in pharmaceutical and food industries  
(Schieber, Stintzing et al. 2001). In this study, we hypothesized that citrus peel may impede cell 
cycle re-entry of quiescent prostate cancer cells and subsequently potential in reducing the risk of 
cancer recurrence.  
The aim of this study was to evaluate the ability of citrus peel extract in inhibiting the quiescent 
prostate cancer cells from re-entering cell cycle using in-vitro assays. To access the overall 
hypothesis, the experimental works were focussed on the following aims: (1) to prepare extracts 
that containing different spectrum of bioactive compounds from citrus peel, (2) to determine the 
anticancer activity of the extract including the ability in halting the cell cycle re-entry of 
quiescent prostate cancer cells, (3) to isolate and identify the bioactive compound(s) in extract 
that are responsible for the cell cycle re-entry inhibitory activity, (4) to evaluate the toxicity of 
extract and isolated compound(s) on normal cell lines, and (5) to identify the modulated proteins 
and signaling pathways at cellular level that are inhibit cell-cycle re-entry of prostate cancer 
cells.  
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2 Citrus as anticancer agent and for cancer 
recurrence prevention 
 
2.1 Cancer 
Cancer is the second main cause of death after cardiac-related diseases. Approximately, 14.1 
million new cases in 2012 were reported worldwide and the number is predicted to increase to 20 
million by 2025 (Ferlay, Soerjomataram et al. 2015). Meanwhile, the mortality rate was about 
8.8 million in 2015 (Ferlay, Soerjomataram et al. 2015). Globally, the frequency of mortality by 
cancer is one in six and about 70% of cancer mortality happen in non-developed countries 
(WHO 2017).  
Cancer is characterized by uncontrolled cellular proliferation resulting from the aberrant activity 
of various cell cycle proteins (Visconti, Della Monica et al. 2016, Otto and Sicinski 2017). The 
uncontrolled proliferation is highly due to the irreversible mutation of DNA that regulate cell 
cycle (Otto and Sicinski 2017). Physical carcinogens (e.g. ultraviolet and ionizing radiation), 
chemical carcinogens (e.g. asbestos, tobacco smoke and arsenic) and biological carcinogens (e.g. 
viruses, bacteria, or parasites) are some of the factors that cause DNA damage (WHO 2018). The 
mutated DNAs express irregular proteins that disturb regulatory pathways and signalling 
cascades. The cells have a selective advantage that allows them to multiply rapidly, acquire 
resistance to apoptosis, develop different cell phenotype and the ability to spread and invade 
other distant organs. The ability of cancer cells to break away from the primary state, travel 
through the bloodstream or lymphatic system to the new site and form a new tumour called as 
metastasis. 
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Cancer can occur in any part of the body as it arises from normal cells. Lung, breast, colon and 
prostate cancer are the top four commonly occurring cancers, which are responsible for 4 in 10 
of all cancers diagnosed worldwide (Ferlay, Soerjomataram et al. 2015). Lung cancer is the most 
commonly diagnosed cancer worldwide for both men and women in 2012 (Figure 2.1). 
Meanwhile, breast cancer and prostate cancer are the second most common cancer diagnosed for 
women and men, respectively.  A similar trend was reported in Australia for 2017, where 
prostate and breast cancer were the most diagnosed cancer for male and female, respectively 
(AIHW 2017).  
 
 
Figure 2.1: Estimated new cancer cases and deaths worldwide by sex and level of economic 
development (Ferlay, Soerjomataram et al. 2013). 
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2.1.1 Cancer recurrence 
Cancer recurrence is defined as the return of cancer after a period of time when cancer couldn’t 
be detected (Li, Rogoff et al. 2015). Cancer recurrence happens with latency periods ranging 
from years to decades. Current cancer treatments fail to destroy the cancer cells and the 
remaining residual cancer cells have the potential to grow into a new tumour. The efficacy of the 
treatment varies between patients as the cancer cells are extremely heterogeneous and have 
different sensitivity to the cancer treatments (Li, Rogoff et al. 2015). Cancer recurrence imposes 
high chance of mortality on cancer patients (Rochat 2009, Feitelson, Arzumanyan et al. 2015).  
The causes and mechanisms for cancer recurrence are not well elucidated. One of the suggested 
causes for cancer recurrence is the presence of quiescent tumour cells (Holmgren, O'Reilly et al. 
1995, Páez, Labonte et al. 2012), which remains after the primary intervention (Aguirre-Ghiso 
2007). Some residual cancer cells enter the G0–G1 phase, develop resistance to chemotherapy 
and escape the immune system. The accumulated transition into quiescence through a G0–G1 
arrest is postulated due to the disruption in the signalling between the cell and surrounding 
microenvironment (Aguirre-Ghiso 2007). However, changes in the microenvironment and any 
other signals could trigger the quiescent cells to re-enter the cell cycle and proliferate. This entry 
of the quiescent cells into the cell cycle is believed to cause cancer recurrence. The mechanisms 
for the transition of disseminated tumour cells that have remained quiescent into a proliferative 
state are still not well understood (Páez, Labonte et al. 2012). Thus, understanding the exit of 
tumour cells from the cell cycle and the re-entry of quiescent tumour cells to cell cycle 
constitutes an important point for intervention in the treatment of cancer and targets for the 
development of a new generation of anti-cancer drugs.    
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2.2 Cell cycle  
The cell cycle consists of four phases known as G1 (growth phase), S (DNA synthesis), G2 
(growth phase) and M (mitosis) as illustrated in Figure 2.2.  Cell cycle progression starts with G1 
phase where the cell will enter either from quiescence phase (G0) or M phase (Vermeulen, Van 
Bockstaele et al. 2003, Visconti, Della Monica et al. 2016, Otto and Sicinski 2017). At G1 phase, 
the cell increases its transcription and translation activity to grow and prepare the cell to 
synthesize DNA at later phase. At S phase, the cell duplicates its DNA content and subsequently 
progresses to G2 phase in preparation for cell division. While at M phase, the cell that has 
duplicated DNA content and organelles will start to divide to form two new daughter cells. 
 
 
Figure 2.2: The cell cycle: phases and the regulator proteins. Progression of the cell through the 
cell cycle phases (G1, S, G2, and M) is promoted by cyclin-dependent kinases (CDKs), which 
are regulated positively by cyclins and negatively by CDK inhibitors (CDKIs) (Schwartz and 
Shah 2005). 
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2.2.1 Cell cycle checkpoints, signalling and regulatory proteins  
Cell cycle progression involves a complex series of molecular and biochemical signalling 
pathways that either stop or progress the cells through the cell cycle. The proteins involved in 
each checkpoint in regulating the cell cycle mechanism are shown in Figure 2.2. The checkpoint 
G1/S at the end of the G1 phase will ensure the cell is free from damaged DNA. Any cell with 
defective DNA is arrested and eliminated thru apoptosis. The second checkpoint is at the G2/M 
phase. A cell with incomplete DNA due to duplication error in S phase is arrested at G2/M 
checkpoint (Otto and Sicinski 2017). 
Progression through checkpoints is controlled by various proteins, mainly cyclin dependent 
kinases (CDKs) and cyclins. A CDK/cyclin complex is formed with the activation of CDK by 
the cyclins that are present only for short periods in the cell cycle (Vermeulen, Van Bockstaele et 
al. 2003, Visconti, Della Monica et al. 2016, Otto and Sicinski 2017). The activated CDK-cyclins 
phosphorylate numerous targets and regulate several processes that allow the release of 
transcription factors required for DNA replication, DNA repair, and cell cycle progression 
(Cobrinik 2005). The activity of Cyclin/CDKs is regulated by endogenous CDK inhibitors, 
which bind to this complex and halts the cell cycle progression (Otto and Sicinski 2017). Cip/Kip 
inhibitors such as p21, p27 and p57 inhibit all cyclin/Cdk complexes, while INK4a inhibitors 
such as p16INK4a p15INK4b p18INK4c p19INK4d and p19/alternative reading frame (ARF) 
inhibit only Cdk4 and Cdk6 (Sherr and Roberts 1999).  
The entry of cell to early G1 phase is induced by different mitogenic signals such as 
RAS/RAF/MAPK pathways, which produces transcription factors such as MYC, AP1 and β-
catenin as shown in Figure 2.3. These transcription factors are required for the production of 
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cyclin D. Three CDKs (2, 4 and 6) and their cyclins (D, E) are responsible for the progression 
through G1. In addition, the retinoblastoma tumour suppressor gene product (Rb) in its active 
state prevents the G1/S transition by binding to the E2F-DP complex. Activated CDK4/6-Cyclin 
D and CDK2/Cyclin E complexes phosphorylate the Rb- E2F-DP complex. This phosphorylation 
subsequently releases the E2F-DP for the transcription of various proteins involved in DNA 
replication leading to entry of cells into S phase (Malumbres and Barbacid 2001). Senescence-
inducing and growth-inhibitory signals inhibit the formation of CDK/Cyclin complex (Otto and 
Sicinski 2017). At the S phase, cyclin A activates CDK2 and allow the progression thru the S-
phase by allowing the production of enzymes and proteins required for DNA synthesis (Schwartz 
and Shah 2005). Levels of cyclins A and B increases at the end of S phase and in G2 phase. At 
the completion of G2 phase, cyclin B/CDK1 complex (also called cyclin B/cdc2) is activated by 
phosphorylation of cdc25c (Schwartz and Shah 2005), which allows the cells to continue mitosis. 
Anaphase-promoting complex (APC)/cyclosome and the degradation of cyclin B control the 
progression thru the mitosis (Ford and Pardee 1999). Inactivation of cyclin B/Ck1 complex 
allows the cells to exit M phase. The daughter cells either progress to G1 phase or exit the cell 
cycle and present in the G0 phase.  
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Figure 2.3: Regulation of G1–S (a) and G2–M (b). Cell cycle transitions are controlled by 
multiple proteins and pathways (Otto and Sicinski 2017). Purple ovals refer to proteins 
promoting cell cycle progression, while blues ovals refer to proteins inhibiting cell cycle 
transition. 
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2.2.2 Drugs targeting cell cycle progression   
One potential strategy for cancer treatment is to use small molecules to disrupt the critical 
cellular machinery required for cell division. In recent years, many drugs targeting the CDKs and 
other cell cycle proteins were developed and tested in clinical trials to restrict the cancerous 
growth. Example of anticancer compounds that target the cell cycle is shown in Figure 2.4. 
Examples of the cell cycle drugs that have been tested in clinical phase are shown in Table 2.1. 
Determining and identifying the full spectrum of proteins involved in cell cycle re-entry from G0 
would be useful in developing new selective drugs that target the quiescent cancer cells. As can 
be seen from Figure 2.4, the transition from G0/G1 to S phase involves the largest number of 
identified proteins, yet there is only one drug that blocks this transition, the 5-Fluouracil (5-FU) 
and its pro-drug, Capecitabine. However, 5-FU acts non-specifically with respect to the cell 
cycle and arrests the cells in G0/G1 by inhibiting the thymidylate synthase, which produces the 
thymidine monophosphate, the active form of thymidine required for the synthesis of DNA. 
Thus, the 5-FU exerts its activity non-specifically by blocking the DNA synthesis in any dividing 
cell which is responsible for its side effects. A new generation of drugs targeting specifically one 
or more proteins involved in the G0/G1-S phase transition may provide a better, more selective 
approach to discriminate cancer cells by exploiting conserved mutations/aberrations in these 
proteins. 
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Figure 2.4:  Examples of anticancer compounds that are used to inhibit cell cycle progression 
(Cyclacel 2018). 
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Table 2.1:  Inhibitors of cell cycle proteins being tested in clinical development (Otto and 
Sicinski 2017). 
Pan-CDK inhibitors 
Flavopiridol*(alvocidib)  
R-roscovitine‡(seliciclib)  
Dinaciclib* (SCH 727965/ MK-7965)  
AT7519*(AT7519M)  
Milciclib‡ (PHA-848125/ PHA-848125AC)  
TG02‡  
CYC065‡  
RGB-286638*  
CDK4- and CDK6-selective inhibitors 
Palbociclib‡(PD0332991)  
Ribociclib‡(LEE011)  
Abemaciclib‡(LY2835219)  
Checkpoint kinase1 and WEE1 protein inhibitors 
MK-8776* (SCH 900776)  
LY2606368*(prexasertib)  
AZD1775‡ (MK-1775)  
GDC-0575‡ (Arry-575)  
Polo-like kinase inhibitors 
Rigosertib* (ON 01910.Na)  
Volasertib* (BI 6727)  
TKM-080301*(TKM-PLK1)  
CFI-400945‡  
Aurora inhibitors 
Alisertib‡(MLN8237)  
ENMD-2076‡  
AMG 900‡  
*Intravenous; ‡oral; 
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2.3 The potential use of bioactive compounds as cell cycle modulators  
Various natural sources have shown promising anticancer activity. This has drawn the interest of 
various researchers to identify and evaluate the bioactive compounds responsible for the 
observed anticancer activity. In fact, the anticancer drugs that are purely natural or derived from 
natural sources made to 49% of all approved cancer therapeutics by the US Food and Drug 
Administration between 1940 and 2014 (Newman and Cragg 2016). Examples of prominent 
anticancer compounds that are being used clinically in the treatment of cancer are Camptothecin 
from Camptotheca acuminate and Taxol from Taxus brevifolia. (Atanasov, Waltenberger et al. 
2015). In recent years, a different class of bioactive compounds were evaluated for anticancer 
activity. The anticancer activity of flavonoids (Wang, Wang et al. 2014, Kaur and Kaur 2015, 
Vue, Zhang et al. 2016), limonoids  (Ozaki, Ayano et al. 1995, Miller, Taylor et al. 2000, Kim, 
Jayaprakasha et al. 2012), carotenoids (Nishino, Murakoshi et al. 2009), coumarins (Venugopala, 
Rashmi et al. 2013) and phenolic acids (De, Baltas et al. 2011, Rocha, Monteiro et al. 2012) has 
been intensively investigated. Some of these bioactive compounds have been shown to modulate 
the cell cycle of cancer cells (Singh, Dhanalakshmi et al. 2002).  Therefore, identifying these 
active compounds and the mechanisms through which they exert their activity would be useful 
for the health-care purpose. 
The best examples of anti-cancer drugs that target the cell cycle and have been modelled upon 
natural compounds are the Vinblastine and Colcemid. Vinblastine has been structurally derived 
from the vinka alkaloid Vincristine extracted from the rosy periwinkle (Catharanthus roseus) 
and the Colcemid is structurally related to Colhicin, extracted from the autumn crocus 
(Colchicum autumnale). Both alkaloids bind to tubulin and disrupt the mitotic spindle leading to 
arrest in G2/M and subsequent cell death by apoptosis. These examples provide a proof of 
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concept and validate a mechanism of action that is effective against cancer. The research in this 
thesis has drawn motivation from these examples and aims to discover natural compounds that 
block the transition from the quiescent state which is more relevant to the reactivation of 
remaining dormant cancer cells responsible for the episodes of relapse in many types of blood 
cancers and carcinomas.  
 
2.4 Citrus and cancer 
Citrus belongs to the family of Rutaceae and it is one of the most common fruits consumed 
widely across the world. The most produced citrus fruits are sweet orange (C. sinensis), 
mandarins (C. reticulate), lemons (C. limon) and limes (C. aurantifolia), grapefruit (C. paradisi) 
and pommelo (C. grandis or C. maxima) (Spiegel-Roy and Goldschmidt 1996). Annual 
production of citrus is increasing each year and has reached about 124 million in 2016, of which 
oranges were the most major citrus fruit accounting for about 67 million tons (Figure 2.5) (FAO 
2017).   
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Figure 2.5: World production of citrus fruits (M tonnes) for the year 2007 to 2012 (FAO 2017). 
  
As shown in Figure 2.6, the structure of citrus fruits includes flavedo, albedo, seed and pulp 
(Spiegel-Roy and Goldschmidt 1996). The edible part is the pulp that contains the juice. Citrus 
fruits are mainly consumed in the form of fresh fruits and in processed forms such as citrus juice. 
Approximately, an average of 34% of citrus fruits produced worldwide is processed to juices, 
although this can reach up to 96% in major citrus producing countries (Bovill 1996). In citrus 
fruits processing industry, a large amount of citrus by-product waste is generated and this waste 
is mostly underutilized. This waste could account for 50% of the fruit weight (Marín, Soler-
Rivas et al. 2007). Citrus peel alone contributes nearly 40% of the total weight of the fruit (Li, 
Lo et al. 2006). In the United States alone, the juice industry produced about 700,000 tonnes of 
peel waste annually (Manthey and Grohmann 2001). 
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Figure 2.6: Parts of citrus fruit. 
 
Citrus is well known for containing high amounts of vitamin C; however, recent studies showed 
that citrus fruits also contain significant amounts of various bioactive compounds (Silalahi 2002, 
Manners 2007, Tripoli, Guardia et al. 2007, Gonzalez-Molina, Dominguez-Perles et al. 2010). 
Citrus fruits contain different groups of bioactive compounds where some of these exerts a range 
of biological effects that improve human health including anti-oxidant, anti-inflammatory, anti-
obesity, anti-diabetes, and cardioprotective and chemopreventive against cancer (Yu, Wang et al. 
2005, Aggarwal and Shishodia 2006, Meeran, Ahmed et al. 2010, Mehta, Murillo et al. 2010, 
Lee, Cha et al. 2011, Aruoma, Landes et al. 2012, Chanet, Milenkovic et al. 2012, Coelho, 
Hermsdorff et al. 2013, Zou, Xi et al. 2016). Moreover, some of these bioactive compounds are 
found in higher concentration in the peel than in the juice (Peleg, Naim et al. 1991, Miyake, 
Murakami et al. 1999, Wang, Chuang et al. 2008, Zhang, Wu et al. 2014). 
Flavedo 
Albedo 
Seed 
Pulp 
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As citrus peel contains a higher amount of bioactive compounds than the other parts of the fruit, 
there is a growing interest and industry drive to utilize citrus peel in a more efficient way. One of 
the potential uses of citrus peel is as an anticancer agent. Several epidemiological studies have 
demonstrated an inverse association of citrus fruit consumption with cancer occurrence (Hakim, 
Harris et al. 2000, Li, Kuriyama et al. 2010, Ferrís-Tortajada, Berbel-Tornero et al. 2012, 
Giacosa, Barale et al. 2013, Cirmi, Ferlazzo et al. 2016, Capurso and Vendemiale 2017). The 
anticancer properties of citrus peel extract (CPE) have been evaluated in both in-vitro and in-vivo 
models, which revealed various anticancer activities including cell proliferation inhibitory effect 
in different cancer types (Cirmi, Ferlazzo et al. 2016, Cirmi, Maugeri et al. 2017). It is 
noteworthy that whole CPE has been shown to have higher anticancer activity than the 
fractionated extracts and single compounds (Mak, Wong-Leung et al. 1996, Ko, Jang et al. 2010, 
Zhang, Wu et al. 2014). Thus, citrus waste is potential to be turned to functional food for the 
cancer patients; however, sufficient investigation on the effect of citrus and its derived products 
on cancer still needed.   
 
2.5 Mechanism of anticancer activity of CPE   
Cancer cells differ from normal cells by their ability to proliferate without control, resistance to 
cell death, ability to form new blood vessels and metastasize to other parts of the body. CPEs 
have been shown to regulate these events through modulation of various cellular proteins as 
illustrated in Figure 2.7. As this study was focussed only on the anti-proliferation activity, 
detailed mechanism of action of CPE on different anti-proliferation proteins are described in 
detail on following in the coming section.   
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Figure 2.7: Main mechanisms through which CPE may act as anti-cancer drugs.  
 
2.5.1 Anti-proliferation activity 
Loss of controlled cell proliferation is the main attribute of cancer cells. CPEs suppress cancer 
cell proliferation by arresting cell cycle progression and modulating cell proliferation signalling 
pathways.   
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2.5.2 Modulation of growth signalling pathways 
Down-regulation of certain oncoproteins such as epidermal growth factor receptor, Ras and Akt, 
which are involved in mitogen-activated protein kinases (MAPK), phosphatidylinositol 3-kinase 
(PI3K) and mechanistic target of rapamycin (mTOR) signalling pathways inhibits cell 
proliferation and growth. CPE reduced proliferation of Hep3B cells by inhibiting the 
phosphorylation of PI3K and Akt that suppresses PI3K/AKT pathways while increasing the 
phosphorylation of ERK1/2, JNK and p38 MAPK that activates MAPK pathways (Hong, Lee et 
al. 2017). Suppression in the phosphorylation of Akt in U937 cells (Han, Lee et al. 2012) and 
mTOR by the CPE was also observed in SNU-1 cells  (Moon, Kim et al. 2015). The inhibition in 
the proliferation signalling was also reported in the in-vivo model. CPE exerted suppression in 
the proliferating signalling through modulation of various proteins including Akt, Ras, ERK1/2 
and E-cadherin in colon tumour-bearing mice (Lai, Tsai et al. 2011). These mice also showed 
low levels of inactive glycogen synthase kinase-3β (GSK-3β) and low accumulation of β-catenin 
in cell nuclei, which limits the growth signalling pathways. CPEs were also reported to reduce 
the ornithine decarboxylase enzyme, which controls the cell growth and proliferation through the 
biosynthesis and metabolism of polyamines, in several in-vivo studies (Lai, Tsai et al. 2011, Pan, 
Li et al. 2012, Lai, Li et al. 2013a).     
 
2.5.3 Inhibition of cell cycle progression 
Cell cycle progression is a highly regulated complex event and consisting of four phases, G1, S, 
G2 and M (Molinari 2000). Progression of cells from one phase to another is controlled through 
the coordinated interaction of cyclin-dependent kinases (CDKs) and their cyclin subunits to form 
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active complexes. The formation of the active complex is regulated by the endogenous CDK 
inhibitors. In normal cells, the cell cycle progression is halted when faulty DNA needs to be 
repaired or when cell division is not required. By halting the cell cycle progression, the growth of 
malignant cells can be reduced or stopped. Analysis of cell cycle distribution in CPE treated cells 
demonstrated that CPE caused cell cycle arrest mainly at G2/M phase (Lee, Park et al. 2012, 
Park, Park et al. 2012, Adina, Goenadi et al. 2014, Nagappan, Lee et al. 2016, Hong, Lee et al. 
2017), although two studies showed accumulation at G1 (Moon, Kim et al. 2015, Chu, Chen et 
al. 2017). It was observed that CPE reduced the number of cancer cells either in G1 phase or S 
phase, while simultaneously increased number of cells in the G2/M phase. This difference could 
be due to the collective effect of multiple compounds in the CPE, the concentration of CPE, and 
also the different sensitivities of cancer cells to the extract.  
At the G1/S transition, the cyclin-dependent kinase inhibitor (p21) silences the cyclin E/CDK2 
complex and causes a G1 arrest. The p21 is directly regulated by the tumour suppressor gene 
p53. CPEs have been shown to up-regulate the expression of p21 and/or p53 leading to G1 arrest 
as observed in MCF-7 (Adina, Goenadi et al. 2014), SNU-1 (Moon, Kim et al. 2015), DU145 
cells (Kim, Lee et al. 2017) and in in-vivo CPE treated A549 cells (Adina, Goenadi et al. 2014). 
Cyclin D1, which is overexpressed in many cancers, was reduced in in-vivo CPE treated colon 
cells (Lai, Tsai et al. 2011). Cyclin D1 and cyclin E were reduced in CPE treated DU145 cells 
(Kim, Lee et al. 2017). The proliferating cell nuclear antigen (PCNA) required for the DNA 
synthesis was also reduced by CPE in PC-3 tumour-bearing mice (Lai, Li et al. 2013b). It is 
worth to note that, since the cells at G0 and G1 are both diploid in DNA, it is not possible to 
separate the G0 from G1 fraction by DNA content analysis such as flow cytometry. Hence, an 
effect of CPE on forcing cancer cells exit from the cell cycle and/or impeding cell cycle re-entry 
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of G0 cells cannot be excluded. Further study is needed to verify this important mechanism. For 
the  G2/M transition, the cell division cycle 25C (CDC25C) phosphatase activates the cell cycle 
controller 2 (CDC2, also named as CDK1), subsequently allowing the activated CDC2 to interact 
with cyclin B1 forming CDC2-cyclin B1 complex (Molinari 2000). CPEs have been shown to 
arrest cell cycle at G2/M by increasing the expression of p21 and decreasing the expression of 
cyclin B1, CDC25C, and CDC2 in A549, Hep3B and AGS cells (Lee, Park et al. 2012, Park, 
Park et al. 2012, Nagappan, Lee et al. 2016, Hong, Lee et al. 2017). 
 
2.5.4 Bioactive compounds in citrus 
Citrus peel contains a range of bioactive compounds such as flavonoids, limonoids, coumarins, 
phenolic acids, terpenoids, and carotenoids. Contents of flavonoids (Zhang, Wu et al. 2014), 
coumarins (Miyake, Murakami et al. 1999), carotenoids (Wang, Chuang et al. 2008) and 
phenolic acids (Peleg, Naim et al. 1991) were reported to be higher in the peel than the other 
parts of citrus fruits. The vast number of flavonoids and mixtures of their subclasses, including 
the flavones, flavanones, flavonols, and anthocyanidins are the main bioactive compounds in 
citrus peel. Flavanones being the major flavonoids are present mostly in glycoside form 
(hesperidin, neohesperidin, narirutin, naringin, eriocitrin and neoeriocitrin) compared to 
flavanone aglycones (hesperetin, naringenin and eriodictyol). Flavones are found in low amounts 
in citrus peel. Examples of flavone glycones are diosmin and isorhoifolin, while flavone 
aglycones are luteolin, apigenin, quercitrin and diosmetin. Another class of flavones known as 
polymethoxyflavones (PMFs) are found almost exclusively in the citrus genus (Ko, Jang et al. 
2010). Examples of PMFs are nobiletin, sinensetin and tangeretin. Flavonols such as kaempferol, 
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quercetin, catechin, isorhamnetin and its glycoside flavonols are found in trace amount in citrus 
peel. Meanwhile, anthocyanidins are found only in grapefruit. The main flavonoids in CPE are 
nobiletin, sinensetin, neohesperidin, tangeretin, poncirin, naringin, and hesperidin (Du and Chen 
2010, Lee, Park et al. 2012, Park, Park et al. 2012, Park, Park et al. 2014, Zhang, Wu et al. 
2014). 
It is reported that up to 62 glucoside and aglycone limonoids were found in citrus (Kim, 
Jayaprakasha et al. 2012). Obacunone glucoside and nomilin acid glucoside are the major 
limonoid glucosides in CPE (Tian, Dai et al. 2000). Coumarins are another class of bioactive 
compounds largely present in citrus peel. Coumarins such as 7-methoxy-8-(2-oxo-3-methylbutyl) 
coumarin, 5-geranyloxy-7-methoxycoumarin, auraptene, limettin and epoxyaurapten, as well the 
furanocoumarins such as psoralen, xanthotoxin, bergamottin and epoxybergamottin were 
reported in citrus peels (Miyake, Murakami et al. 1999, Lim, Moon et al. 2009, Gyawali, Jeon et 
al. 2012, Dugrand, Olry et al. 2013). Cinnamic acids (caffeic, p-coumaric, chlorogenic, ferulic 
and sinapic) and benzoic acids (protocatechuic, p-hydroxybenzoic and vanillic) are phenolic 
acids found in low concentration in citrus peels (Wang, Chuang et al. 2008, Xu, Chen et al. 
2008). Meanwhile, carotenes (β-carotene) and xanthophylls (β-cryptoxanthin, lutein, β-citraurin, 
violaxanthin, (9Z)-violaxanthin and zeaxanthin) are the main carotenoids found mostly in citrus 
peel (Attila, Veronika et al. 2007, Wang, Chuang et al. 2008).   
These bioactive compounds were found to exhibit anticancer activity at different levels by 
modulating various mechanisms when tested both in-vitro and in-vivo studies, suggesting the 
contribution of these compounds to the overall anticancer activity of CPE. Several articles have 
adequately reviewed the anticancer activity of these compounds (Miller, Taylor et al. 2000, 
Manners 2007, Nishino, Murakoshi et al. 2009, Kim, Jayaprakasha et al. 2012, Rocha, Monteiro 
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et al. 2012, Batra and Sharma 2013, Rawson, Ho et al. 2014, Wang, Wang et al. 2014, Kaur and 
Kaur 2015). 
 
2.6 Effect of citrus peel extract on different types of cancer 
CPEs have been reported to show anticancer activity in various cancer cell lines at different 
concentrations, which reflect the CPE composition and the cell line sensitivity. The following 
sections provide an overview of the in-vitro and in-vivo studies in which CPEs have 
demonstrated the potential of reducing the risk of cancer development and progression (Table 2.2 
and Table 2.3). Detailed information about the effect of CPE on different cancers is elaborated in 
the following sections.  
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Table 2.2: In-vitro anticancer effect of citrus peel extract. 
D: Determined; I: Induced, * only for U937, ^ only for DU145, 
#
 only for Hep3B 
Variety Compound 
Identification 
Cell lines (IC50, µg/mL) Cell 
cycle 
arrest 
Anti-
proliferation 
Pro-
apoptosis 
Anti-
metastasis 
Anti-
inflammat
ory & anti-
angiogenes
is 
Reference 
Citrus reticulata D WEHI 3B  (<100)      (Mak, Wong-Leung et al. 1996) 
Citrus reticulata  SNU-668 (≈100)   I   (Kim, Park et al. 2005) 
Citrus sinensis D MCF-7 
(10.2-17.9) 
  I   (Sergeev, Ho et al. 2007) 
Citrus grandis D U937 (60), HepG2 (31), HeLa (287), 
HCT-15 (87), MCF-7 (144), NCI-
H460 (73), SNU-16 (90) 
  I*   (Lim, Moon et al. 2009) 
17 citrus varieties D HT-29 (31-45)      (Hirata, Fujii et al. 2009) 
Citrus sunki D HL-60 (25) G2/M  I   (Ko, Jang et al. 2010) 
Citrus aurantium D AGS (99) G2/M  I I   (Lee, Park et al. 2012) 
Citrus aurantium  U937 (40-60)   I I  (Han, Lee et al. 2012) 
Citrus grandis D HeLa (100-200), AGS (200-400)   I   (Gyawali, Jeon et al. 2012) 
Citrus aurantium D A549 (230) G2/M I I   (Park, Park et al. 2012) 
Citrus unshiu  MDA-MB-231(>200)    I  (Jin, Lee et al. 2013) 
Citrus junos  HT-29 (>1200)     I (Kim, Shin et al. 2014) 
Citrus aurantifolia  MCF-7 (59) G2/M  I   (Adina, Goenadi et al. 2014) 
Citrus aurantium D A549   I I  (Park, Park et al. 2014) 
Citrus hassaku D MDA-MB-231    I  (Kim, Kim et al. 2014) 
Citrus reticulata D HepG2 (20-40), 
HL-60 (25-50), 
MDA-MB-231 (25-50) 
     (Zhang, Wu et al. 2014) 
Citrus paradisi, Citrus 
sinensis, Citrus maxima 
D Caco-2, LoVo, 
LoVo/ADR 
     (Ademosun, Oboh et al. 2015) 
Citrus hassaku D SNU-1 (<25) G1  I   (Moon, Kim et al. 2015) 
Citrus paradesi  Kasumi-1 (2000)   I   (Wang., Lin. et al. 2015) 
Citrus reticulata D SKOV3 (≈ 100)   I I  (Chang, Jia et al. 2015) 
Citrus platymamma D A549 (364) G2/M I I  I (Nagappan, Lee et al. 2016) 
Citrus sphaerocarpa D MDA-MB-231 (>200)    I I (Park, Shin et al. 2016) 
Citrus iyo D U266 (>400), 
K562 (200-400), DU145(>400), MDA-
MB-231(>400), 
HepG2 (200-400), RWPE-1(>400) 
 I^ I^ I^ I^ (Kim, Lee et al. 2017) 
Citrus platymamma D Hep3B (100-200), HepG2 (300-400) G2/M I# I# I#  (Hong, Lee et al. 2017) 
Citrus sinensis D HepG2 (>500) G1 I I   (Chu, Chen et al. 2017) 
Citrus reticulata  HCT116      (Onuma, Asai et al. 2017) 
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Table 2.3: In-vivo anticancer effect of citrus peel extract.  
Sample  Animal models Dose (route) Duration Effects Reference 
Citrus junos    HT-29 cells 
implanted mice  
100 mg/kg/ daily (i.p) 4 weeks Reduced tumor size, 
disease activity index 
and colon shortening  
(Kim, Shin et 
al. 2014) 
Citrus 
aurantium 
A549 cells 
injected in mice 
tail vein   
Twice weekly (i.p) 5 weeks Reduced cancer 
metastasis   
(Park, Park et 
al. 2014) 
Citrus 
reticulata 
Treated leukemic 
cells injected into 
mice 
.  2 or 10 
weeks 
Reduced number of 
tumour cells and 
increased mice survival 
time 
(Mak, Wong-
Leung et al. 
1996) 
Citrus 
sinensis 
AOM-induced 
carcinogenesis in 
mice 
0.2 % in the diet  26 weeks Reduced number and 
size of ACF, tumour 
burden and incidence  
(Wei, Yue et 
al. 2003) 
Citrus 
sinensis 
Western diet 
inducing cancer 
0.25% or 0.5% in diet  9 weeks Reduced tumour 
number, multiplicity 
and induced apoptotic 
(Fan, 
Kurihara et 
al. 2007) 
Multiple 
citrus 
varieties 
DMBA-induced 
carcinogenesis in 
mice 
100 or 200 µL/ twice 
weekly (cream 
application) 
20 weeks Reduced epidermal 
thickness, number of 
papillomas, tumour 
incidence and tumour 
weight 
(Pan, Li et al. 
2012) 
Multiple 
citrus 
varieties 
PC-3 cells 
implanted mice 
1 or 2 mg/kg/ five days 
per week (i.p) and 2 or 
4 mg/kg/ five days per 
week (o.p)  
3 weeks Suppressed tumor size. (Lai, Li et al. 
2013b) 
Multiple 
citrus 
varieties 
AOM-induced 
carcinogenesis in 
mice 
100 or 200 µL / five 
days per week (o.p) 
6 weeks Reduced number of 
ACF 
(Lai, Li et al. 
2013a) 
Citrus iyo DU145 cells 
implanted mice 
50 or 200 mg/kg/ 
thrice weekly (i.p) 
4 weeks Suppressed tumour 
growth 
(Kim, Lee et 
al. 2017) 
Citrus 
sinensis 
HepG2 cells 
implanted mice 
1 or 10 mg/kg/thrice 
weekly in diet 
3 weeks Reduced tumour 
growth 
(Chu, Chen et 
al. 2017) 
Citrus 
sinensis 
AOM-induced 
carcinogenesis in 
mice 
0.01 or 0.05% in diet 4 or 18 
weeks 
Reduced number of 
ACF 
(Lai, Tsai et 
al. 2011) 
i.p: intraperitoneal injection; o.p: oral injection; ACF: aberrant crypt foci; AOM: azoxymethane; 2, 4-
dimethoxybenzaldehyde  
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2.6.1.1 Lung cancer 
Among different solvent fractions of CPE, hexane fraction was the most potent fraction when 
tested in lung cancer U937 cells. Subsequently, the fraction was tested on different cancer lines 
and NCI-H460 cell growth was strongly inhibited by the fraction (Lim, Moon et al. 2009). In 
A549 cells, the CPE dose-dependently inhibited cell proliferation while inducing apoptosis 
(Nagappan, Lee et al. 2016). Similar inhibitory effects were also observed with flavonoid-rich 
CPE in A549 cells (Park, Park et al. 2012). However, weak proliferation inhibitory effect was 
observed in normal W1-38 fibroblast cells indicating specify of the CPE. In another study, the 
CPE showed anti-metastatic properties by preventing the migration of A549 cells to the wounded 
area in the in-vitro experiment (Park, Park et al. 2014). Similar behaviour was observed in the in-
vivo model where the CPE prevented the A549 cells in the tail vein from migrating to lungs, 
indicating anti-localization and anti-metastatic properties of CPE.    
 
2.6.1.2 Breast cancer 
CPEs exhibited anticancer activity in both estrogen-dependent and -independent breast cancer 
cells.  CPE showed proliferation inhibition and apoptosis activity in estrogen receptor positive 
MCF-7 cells (Adina, Goenadi et al. 2014). Moreover, the combination of this CPE and 
doxorubicin exhibited a synergistic effect in inducing apoptosis. Thus, the use of the anticancer 
drug at a low dose for optimum efficacy with minimal side effects in cancer patients is possible 
with CPE intake. However, studies are needed in this area. Meanwhile, the potent hexane 
fraction of CPE showed moderate anti-proliferation activity on MCF-7 cells (IC50: 144 µg/mL) 
compared to colon, lung, stomach, cervical, hepatoblastoma and lymphoma cancer lines (60-287 
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µg/mL) (Lim, Moon et al. 2009). In another study, hydroxylated PMFs rich CPE showed lower 
anti-proliferation and higher apoptosis activity than non-hydroxylated rich PMFs CPE (Sergeev, 
Ho et al. 2007). The IC50 values for these PMFs rich CPEs were in the range of 10.2 - 17.9 
µg/mL. The difference in the IC50 values between these two studies could be due to PMF content 
as Lim, Moon et al. (2009) found the PMF content in hexane fraction was lower than in the other 
fractions.   
Meanwhile, for hormone-independent breast cancer, CPE showed strongest anti-proliferation 
effect in MDA-MB-231 than in HepG2 and HL-60 cells (Zhang, Wu et al. 2014). Interestingly, 
when six isolated flavonoids tested individually at 20 µg/mL, only 5-demethylnobiletin showed 
the almost equivalent anti-proliferative effect as the CPE, while the other flavonoids showed 
weak or no anti-proliferative effect. In contrast, CPE obtained using supercritical carbon dioxide 
reduced MDA-MB-231 cells proliferation by less than 20% at 400 µg/mL (Kim, Lee et al. 2017). 
Limonene was the major compound in supercritical carbon dioxide CPE. However, the CPE at 
100 µg/mL significantly prevented MDA-MB-231 metastasis and invasion (Kim, Kim et al. 
2014). Interestingly, only one study evaluated anticancer activity of polysaccharides from citrus 
peel in cancer. Polysaccharides from CPE showed anti-metastatic activity in MDA-MB-231 cells 
with cell proliferation inhibition activity of 30% at 100 µg/mL (Park, Shin et al. 2016). Similarly, 
flavonoid rich CPE showed the anti-metastatic effect by significantly inhibiting MDA-MB-231 
cell adhesion to HUVECs of the low dose of 10 μg/ml, although proliferation suppression of 
MDA-MB-231 cells was not significant at concentration up to 100 μg/ml (Jin, Lee et al. 2013). 
Moreover, the polysaccharides from CPE possesses anti-angiogenetic properties, as the CPE 
reduced significantly the tube formation in HUVEC cells without exhibiting cytotoxicity (Park, 
Shin et al. 2016).     
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2.6.1.3 Colon cancer 
CPE showed prominent anticancer activity in colon cancer in both in-vitro and in-vivo studies. 
Hexane fraction of CPE showed strong proliferation inhibitory activity in HCT-15 cells among 
the other tested cancer cell lines (Lim, Moon et al. 2009). In another study, among the 17 
different citrus varieties tested, only four CPEs showed strong cancer cell inhibition activity in 
HT-29 cells (Hirata, Fujii et al. 2009). These CPEs were fractionated using ethyl acetate and 
water. The ethyl acetate fractions inhibited the colon cancer cell growth with the IC50 values in 
the range of 31-45 µg/mL, which are 18-20 folds lower than that of water fractions. This finding 
suggests that the anticancer compounds in citrus peel targeting colon cancer cells are more 
soluble in ethyl acetate than water. 3,5,6,7,8,3’,4’-heptamethoxyflavone was the most potent 
anticancer compound isolated in that study. As reported in the previous study, CPE of Citrus 
junos Tanaka at 1200 µg/mL showed by nearly 30% inhibition activity in HT-29 cells (Kim, 
Shin et al. 2014). In addition, CPE also inhibited metastasis and proteasome activities in Caco-2, 
LoVo and LoVo/ADR colon cancer cell lines (Ademosun, Oboh et al. 2015).   
Aberrant crypt foci (ACF) is considered as a histological biomarker for colon carcinogenesis and 
the risk of cancer development increases with a number of incidence and multiplicity of ACFs in 
colon cancer tissue (Rawson, Ho et al. 2014). In one study, mice were fed with a diet containing 
0.2% of CPE before carcinogen injection, during, and continuing to end of the experiment (Wei, 
Yue et al. 2003). The mice with CPE diet showed a reduction in the number of ACF/colon, 
AC/colon, colon tumours and colon tumour incidence by 34-66% compared with control. The 
low incidence of tumour development could be due to the highly potent PMFs. The extract 
contains approximately 30% of PMFs and also other monohydroxylated analogues of the PMFs. 
In another study, the addition of CPE at 0.25 or 0.5% to the new western-style diet reduced the 
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overall number of the tumor by 26-48% and overall tumour volumes by 36-63%, and also 
increased the number of apoptotic cells, when compared to the western-style diet alone (Fan, 
Kurihara et al. 2007). These data indicate that CPEs rich in PMFs can reduce tumorigenesis and 
enhance apoptotic activity in colon cancer cells. Meanwhile, feeding the mice with a diet 
containing 0.01% or 0.05% of hydroxylated PMFs for four weeks reduced the total number of 
ACF per colon by 40-44% compared to control (Lai, Tsai et al. 2011). When the mice were fed 
with hydroxylated PMFs for 20 weeks, the number of microadenomas was reduced by up to 81% 
compared to control. It is unclear for the factors that contribute to tumour incidence as some 
studies showed a reduction in the tumour formation incidence and while some studies are not. 
The extract contains 89.3% of hydroxylated PMFs and the intake of a small number of 
hydroxylated PMFs within a short period of consumption could be sufficient to exhibit their 
anticancer activity. Similarly, oral administration of CPE rich with PMFs, naringin and 
hesperidin reduced numbers of ACF and large ACF up to 40% compared to the control group in 
a colon tumour-bearing mice (Lai, Li et al. 2013a). It is worth mentioning that the methoxy 
group of PMFs could undergo auto-hydrolysis during long term storage (Qiu, Dong et al. 2010), 
suggesting that the anticancer activity may increase with time.  
In another study, oral administration of CPE at 100 mg/kg·day improved colon shortening and 
disease activity index by reducing COX-2 expression, and significantly reduced the size of an 
HT-29 tumour in xenografts mice (Kim, Shin et al. 2014). The author suggested CPE has 
potential in preventing inflammation-related disease including colon cancer. Moreover, 
administration of dried citrus peel at a dose of 1,000 ppm in the diet reduced total ACF by 25% 
compared to control (Onuma, Asai et al. 2017). The antioxidant potential of CPE prevents the 
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colon carcinogenesis at the initiation stage as levels of reactive carbonyl species were 
significantly reduced in the serum of F344 rats.  
As colon cancer develops from a small number of slow-growing benign polyps, it is well suited 
for dietary or classical, chemopreventive type of interventions and several studies have 
demonstrated this effect with aspirin, which is derived from salicylic acid, ubiquitously occurring 
in many plants. The demonstrated beneficial effect of CPEs on colon cancer justifies further 
investigation for its potential use as a dietary supplement with chemo-preventive activity. 
 
2.6.1.4 Stomach cancer 
CPEs demonstrated potential in inhibiting stomach cancer. CPEs suppressed proliferation by 
50% in SNU-668 (Kim, Park et al. 2005), AGS (Lee, Park et al. 2012) and SNU-16 (Lim, Moon 
et al. 2009) at a concentration around 100 µg/mL by exerting cell cycle arrest and inducing 
apoptosis in in-vitro. The CPE had no toxicity effect to normal mouse embryo fibroblast cells 
(3T3-L1) when tested up to 500 µg/mL (Kim, Park et al. 2005).  However, for CPE obtained 
using supercritical carbon dioxide extraction, the proliferation of AGS cell decreased by 
approximately 30% at 200 µg/mL (Gyawali, Jeon et al. 2012). On the other hand, CPE obtained 
with similar extraction technique induced apoptosis and inhibited SNU-1 cells with an IC50 value 
lesser than 25 μg/mL (Moon, Kim et al. 2015). The predominant compound in this CPE was 
auraptene, although limonene is the major compounds in CPE obtained by supercritical carbon 
dioxide. The auraptene could be the main anticancer compound in the CPE as it showed 
strongest proliferation inhibition effect on SNU-1 (IC50: ≤ 7.5 μg/mL) compared to other 
different cancer cell lines and no toxicity was observed on HEK-293T.    
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2.6.1.5 Skin cancer 
Only one study evaluated the anticancer activity of CPE on skin cancer. Two-stage skin 
carcinogenesis model was used where the mice were treated with 7,12-
dimethylbenez[a]anthracene to initiate tumours, followed by repeated application of 12-O-
tetradecanoylphorbol 13-acetate to promote a skin tumour. Topical application of CPE at 100 µL 
and 200 µL on the skin of mice suppressed epidermal thickening by 23-33% when compared 
with control (Pan, Li et al. 2012). Mice with topical application of 100 µL of extract also had a 
reduction in the number of papillomas by 25%, tumour incidence by 18%, tumour weight by 
65% and a number of tumours with a diameter of above 5 mm by 33% when compared to the 
control group.  The author suggested the anticancer properties of CPE are through down-
regulation of inflammation, proliferation and angiogenesis. 
 
2.6.1.6 Liver cancer 
CPE showed proliferation inhibitory activity in HepG2 cells (Lim, Moon et al. 2009, Zhang, Wu 
et al. 2014). Meanwhile, among the five cancer lines tested, HepG2 cells were strongly inhibited 
by the supercritical carbon dioxide CPE (Kim, Lee et al. 2017). Also, the supercritical carbon 
dioxide CPE was more effective in inhibiting the Hep3B than that in HepG2 cells (Hong, Lee et 
al. 2017). The proliferation of Hep3B was dose-dependently reduced from 25 µg/mL, whereas 
for HepG2 it was reduced from 400 µg/mL. The CPE also induced apoptosis and cell metastasis 
in Hep3B cells. Chu, Chen et al. (2017) also showed the CPE at 500 µg/mL had moderate 
proliferation inhibition activity while inducing apoptosis in HepG2 cells. The CPE reduced the 
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HepG2 tumour growth when tested in the in-vivo model; however, the CPE did not diminish the  
tumour as effective as in prostate cancer-bearing mice. 
 
2.6.1.7 Cervix cancer 
CPE obtained using supercritical carbon dioxide extraction exhibited stronger anticancer activity 
in HeLa cells than AGS cells with IC50 value between 100 and 200 µg/mL (Gyawali, Jeon et al. 
2012). In contrast, the hexane fraction of CPE showed the weakest inhibition activity in HeLa 
cells with an IC50 value of 286 µg/mL compared to the other cancer lines (Lim, Moon et al. 
2009). Although the citrus species used in both studies were the same, the different inhibition 
activity was due to different extracted compounds and it clearly shows the importance of 
consuming the whole CPE for maximum efficacy. Meanwhile, CPE not only inhibited SKOV3 
cell proliferation but also suppressed the motility of SKOV3 cells by inhibiting epithelial-to-
mesenchymal transition (EMT), which is related to metastasis (Chang, Jia et al. 2015). This is in 
support with another finding where nobiletin and tangeretin inhibited the SKOV3 ovarian cells 
migration (Zhang, Wu et al. 2014). 
 
2.6.1.8 Leukaemia 
CPE has potential in reducing the risk of leukaemia, a cancer of the white blood cells. In one 
study, CPE showed significant proliferation inhibition in HL-60 cells at a concentration as low as 
25 µg/mL (Zhang, Wu et al. 2014). The HL-60 cells exhibited strongest responsive to the six 
isolated flavonoids from the CPE, where the proliferation inhibition activity was significant even 
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at 0.8 µg/mL. Also, CPE reduced survival of Kasumi-1 cells with the IC50 value of 2000 µg/mL 
(Wang., Lin. et al. 2015). The high IC50 could be due to the lower sensitivity of Kasumi-1 cells 
or due to loss of some potent compounds in the water fraction during the fractionation. 
Combination of this CPE with arsenic trioxide showed a greater effect against the proliferation of 
Kasumi-1 cells than that of individual treatments. CPE also suppressed U937 cells proliferation 
by inducing apoptosis (Han, Lee et al. 2012). Supercritical carbon dioxide produced CPE exerted 
strong proliferation inhibition effect in K562 cells compared to the other four cancer lines (Kim, 
Lee et al. 2017).  
In another study, diethyl ether fraction of CPE exhibited slightly stronger inhibition activity in 
WEHI 3B cells than the water fraction (Mak, Wong-Leung et al. 1996). The CPE also 
differentiated the WEHI 3B cells to macrophages and polymorphonuclear cells, which is one of 
the therapeutic goals in the treatment of leukaemia. As expected, crude CPE induced higher 
differentiation of WEHI 3B cells than the diethyl ether and water fractions. The authors 
suggested that methoxylated flavonoids, nobiletin and tangeretin, are the potential anti-leukemia 
compounds for various forms of myeloid leukaemia. The WEHI 3B cells, which were treated 
with diethyl ether fraction of CPE, showed slower tumour growth when inoculated in mice and 
the extract also prolonged the survival time of mice (Mak, Wong-Leung et al. 1996).  
On the other hand, hexane fraction of CPE showed highest anti-proliferation activities via 
induction of apoptosis in U937 cells compared to the other six cancer lines (Lim, Moon et al. 
2009). Consistent with the previous study, hexane fraction of CPE and the isolated flavonoids 
(nobiletin and 5-demethyltangeretin) showed greater growth inhibitory activity in HL-60 with 
IC50 value in the range of 20-25 µg/mL than the other flavonoid components which had IC50s of 
above 100 µg/mL (Ko, Jang et al. 2010). The hexane fraction and 5-demethyltangeretin also 
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induced higher levels of apoptosis compared to the other tested PMFs. The author further 
suggested that hot water extraction is more efficient in extracting PMFs than organic solvent 
extraction.   
The concept of minimal residual disease (MRD), or the residual load of remaining blast cells that 
usually survive chemotherapy and are responsible for the future remission episodes, was first 
derived from leukaemia. Therefore, animal models of MRD represent the ideal systems to test 
the effectiveness of CPEs to suppress the cell-cycle re-entry of residual blast cells.  
 
2.6.1.9 Prostate cancer 
Prostate cancer is the most common cancer in man. CPE showed a strong anticancer effect in 
prostate cancer by inhibiting the tumour growth in an in-vivo mouse model (Lai, Li et al. 2013b, 
Kim, Lee et al. 2017). CPE produced using supercritical carbon dioxide extraction at 400 µg/mL 
exerted a moderate effect in the proliferation of DU145 cells by modulating STAT3 pathway and 
no effect in normal prostate RWPE-1 cells  (Kim, Lee et al. 2017). When the CPE was tested in 
mice model at a dosage of 50 and 200 mg/kg, the growth of the implanted DU145 tumour in 
mice was significantly reduced. The reduction is in parallel with reductions in the proteins 
related to proliferation and angiogenesis. Similarly, in another study, treatment with CPE by 
intraperitoneal injection or oral administration in PC-3 tumour-bearing mice reduced the tumour 
weight by 57–100% and tumour volume by 78–94% compared to control (Lai, Li et al. 2013b).  
The strong anticancer activity of the extract was suggested to be due to the high concentration of 
PMFs and also the other compounds such as hesperidin. Remarkably, the tumour was almost 
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undetectable for mice treated with 2 mg/kg·day by intraperitoneal injection. However, the 
intraperitoneal injection at 1 mg/kg·day showed lower tumour suppression than with oral 
administration at 2 mg/kg/day. Both studies showed strong anticancer activity in prostate cancer 
cells. The intraperitoneal injection of CPE had a higher reduction of prostate tumour size than the 
oral administration indicating the needs to understand the bioavailability of the bioactive 
compounds is crucial in order to have maximum anticancer potency of CPE. 
As prostate cancer is the most frequent malignant disease in men, is associated with high 
morbidity but develops slowly over many years and has a clear biomarker for its progression (the 
PSA), it is well suited for interventions based on cell-cycle inhibitors and particularly those 
derived from natural compounds, with good dietary representation such as compounds present in 
CPEs. Therefore, prostate cancer was selected as a primary focus in this study. 
 
2.7 Prostate cancer incidence 
Prostate cancer is the second most common cancer diagnosed for men and the fifth leading cause 
of cancer death worldwide (Ferlay, Soerjomataram et al. 2015, Torre, Bray et al. 2015). About 
1.1 million men were diagnosed with prostate cancer in 2012 with 307000 deaths worldwide 
(Ferlay, Soerjomataram et al. 2015). This number represents the 15% of all cancers diagnosed in 
men worldwide and the prostate cancer incidence occurred mainly in the more developed regions 
accounting about almost 70% of the cases (Torre, Bray et al. 2015). Prostate cancer incident rate 
varied by more than 25-fold in different parts of the world. Australia and New Zealand were 
ranked in the top of the list, while South-Central Asia was the country with the lowest prostate 
cancer incidence (Figure 2.8). This high incidence is mainly because of improving detection 
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using prostate-specific antigen (PSA). However, mortality in these regions is lower or almost 
equal to those with low incidence rates. Interestingly, Eastern and South-Central Asia showed 
the lowest incidence and mortality rates (Torre, Bray et al. 2015). In contrast, the Caribbean and 
Africa showed the highest mortality rates for prostate cancer.   
 
 
Figure 2.8: Estimated age-specific incidence and mortality rates for prostate cancer in 2012  
(Torre, Bray et al. 2015). 
 
Prostate cancer is estimated to be the most commonly diagnosed cancer for males in Australia 
for the year 2017 (AIHW 2017). The number of men estimated to be diagnosed with prostate 
cancer in Australia in 2017 was 16665 with 3452 mortality cases (AIHW 2017). The prevalence 
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and mortality of prostate cancer at different ages in Australia for 2017 were shown in Figure 2.9. 
The risk of prostate cancer increases dramatically at age 40 and above, where elderly men 
contribute to the high mortality rates (AIHW 2017). Meanwhile, the 5-year relative survival for 
prostate cancer patients in Australia increased from 58% to 95% during the year 1984–1988 and 
2009–2013 (Figure 3b) (AIHW 2017).  
 
Figure 2.9: Estimated age-specific incidence and mortality rates for prostate cancer in Australia 
for the year 2017 (a), and 5-year relative survival from prostate cancer, 1984–1988 to 2009–
2013, in Australia (b) (AIHW 2017). 
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The most common treatments for prostate cancer are active surveillance, surgery, radiotherapy, 
cryosurgery, chemotherapy and immunotherapy. Active surveillance rather than immediate 
radical treatment such as radical prostatectomy or radiation therapy is a preferable and 
reasonable approach for men with less-aggressive tumour-bearing, old, or with serious co-
morbid conditions. For prostate cancer at an earlier stage, radical prostatectomy or radiation 
therapy is the primary curative treatment procedure. While for advanced prostate cancer, 
hormone therapy is preferred. At the initial stage, androgen deprivation therapy could block the 
androgen receptor pathway and induces tumour regression (Nieto, Finn et al. 2007). The prostate 
cancer becomes more severe and untreatable when it is irresponsive to androgen hormones  
(Feldman and Feldman 2001). Although the primary treatment could stop the prostate cancer 
progression, the cancer patients are more likely to experience cancer recurrence and ultimately 
develop metastatic disease. Meanwhile, chemotherapy is not commonly used for prostate cancer; 
but it is used when prostate cancer is beyond the prostate gland and hormone therapy is not 
responsive. These treatments frequently cause undesirable side effects to the patients (Penson, 
Litwin et al. , Eton and Lepore 2002).   
 
2.7.1 Prostate cancer recurrence 
Like the other types of cancer, prostate cancer is likely to recurrent in patients where 
approximately 35% of men experience a recurrence within 10 years following radical 
prostatectomy (Freedland, Humphreys et al. 2005). The prostate cancer recurrence is identified 
by the rise in serum prostate-specific antigen (PSA) levels, which requires immediate secondary 
treatment (Freedland, Humphreys et al. 2005). The rise in the PSA level is associated with severe 
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risk of fatality and the treatment can significantly reduce the quality of life. Prostate cancer 
recurrence with advanced hormone-refractory metastatic cancer was a high risk of fatality 
(Radhakrishnan, Miranda et al. 2010). Prostate cancer is the fifth leading cause of cancer death 
worldwide despite the improved 5-year relative survival rate (Bray, Ferlay et al. 2018). The 
median time for the cancer metastasis is six years from the time of initial prostate-specific 
antigen (PSA) elevation (Yamamoto, Musunuru et al. 2016), followed by a death. The long 
median time allows the potential use of other supplementary interventions to delay or prevent 
cancer recurrence.  
  
2.7.2 Prostate cancer epidemiology and diet 
Mounting evidence, both epidemiologic and laboratory studies, suggest the role of food in 
modulating cancer occurrence. According to a study conducted by American Institute for Cancer 
Research and the World Cancer Research Fund in 1997, cancer occurrence can be reduced by 
30–40% with appropriate diets and lifestyle (Potter 1997, Anand, Kunnumakkara et al. 2008). 
Epidemiologic studies suggest that consumption of a bioactive-rich diet that includes fruits and 
vegetables could reduce the risk of cancer (Chan, Gann et al. 2005). In particular, risk of prostate 
cancer occurrence is lowered with high intake of vegetables, fruits, fish, and specific component 
nutrients in these foods such as tomatoes/lycopene, carotenoids, cruciferous vegetables, vitamin 
E, selenium, fish/marine omega-3 fatty acids, soy, isoflavones and polyphenols (Chan and 
Giovannucci 2001, Giovannucci 2002, Chan, Gann et al. 2005). In one cohort study, men 
consuming more than two servings of tomato sauce per week lowered their risk of developing 
prostate cancer by 20–35% (Giovannucci, Rimm et al. 2002). Moreover, a population-based 
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case-control study carried out in men in western Washington state showed three or more servings 
of cruciferous vegetable consumption per week statistically decreases the risk of prostate cancer 
by 41% (Cohen, Kristal et al. 2000).  
Nutritional intervention is often adapted to cancer patients to facilitate cancer therapy. Changing 
the diet could be favourable to cancer patients in maintaining health and improving the quality of 
life, and also in preventing cancer recurrence (Brown, Byers et al. 2001). It has been shown that 
many men after being diagnosed with prostate cancer altered their diet and lifestyle with the 
hope to delay prostate cancer recurrence (Brown, Byers et al. 2001). Supplementation of 
lycopene to the men with newly diagnosed localized prostate cancer prior to surgery decreased 
their PSA levels (Kucuk, Sarkar et al. 2001). Similarly, the slow progression of prostate cancer 
was correlated with intake of cruciferous vegetable by patients after diagnosis (Richman, Carroll 
et al. 2012). Chan, Holick et al. (2006) also found a moderate correlation between vegetable 
consumption after post-diagnostic with the risk of prostate cancer progression. Although a strong 
and clear association of certain foods with prostate cancer progression could not be established at 
this stage, most of the epidemiology studies show the ability of some foods and compounds 
derived from them to decrease cancer incidence and recurrence. Therefore, identifying the 
promising foods or bioactive compounds would be a significant deal in not only altering the risk 
of developing prostate cancer but also in modulating its recurrence and progression. Among 
many fruits and vegetables, citrus is a promising candidate with potential for developing a 
functional food or nutraceutical supplement for chemoprevention and management of prostate 
cancer.   
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3 Citrus peel extract in halting cell cycle re-entry 
of quiescent prostate cancer cells. 
 
3.1 Introduction    
Cancer is one of the leading chronic diseases globally with a high mortality rate (Torre, Bray et 
al. 2015). Despite significant advancement in the early detection and treatment of cancer, the 
current therapies still could not eradicate the risk of cancer recurrence and metastasis (Li, Rogoff 
et al. 2015). Cell cycle re-entry of residual quiescent cancer cells has been implicated as a major 
cause of cancer recurrence and metastasis (Goss and Chambers 2010, Páez, Labonte et al. 2012). 
Thus, arresting and preventing these quiescent cancer cells from proliferating could delay the 
cancer recurrence.  
It has been shown that many natural bioactive compounds are able to halt the progression of 
cancer at different carcinogenesis phase including arresting cells at various cell cycle 
checkpoints (Singh, Dhanalakshmi et al. 2002). As an example, flavonoids exhibit a broad 
spectrum of anti-cancer activities by interfering in the initiation, promotion and progression of 
cancer through different mechanisms such as anti-proliferation, anti-inflammation, anti-
angiogenesis, anti-metastasis, pro-apoptosis and reversal of multidrug resistance (Batra and 
Sharma 2013, Ravishankar, Rajora et al. 2013). The cell cycle arrest activity of flavonoids 
provides an opportunity in preserving quiescent cancer cells.   
Citrus peel has been used traditional medicine for treating many diseases (Xu, Chen et al. 2008, 
Rawson, Ho et al. 2014). The results of previous in-vitro and in-vivo studies on various cancer 
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cell lines demonstrate that citrus peel is one of the rich sources of flavonoids and has anticancer 
activity (Wang, Wang et al. 2014). As no information about the ability of citrus peel in arresting 
quiescent cells is available, in this study we aimed to have a new approach compared with 
previous studies and hypothesized that flavonoid rich citrus peel could inhibit quiescent cancer 
cells from proliferating, therefore, can potentially reduce the risk of cancer recurrence. The 
outcomes of this study will enable to develop a naturally derived product from citrus peel extract 
(CPE) that can be used for patients after chemotherapy to reduce the risk of cancer recurrence.   
 
3.2 Materials and methods 
3.2.1 Chemicals and reagents 
Hoechst 33342 (B2261), Pyronin Y (P9172), RNase A from bovine pancreas (10109142001), 
DMSO (D8418) and Annexin V-FITC Apoptosis Detection Kit (APOAF-20TST), hexane 
(270504), ethyl acetate (34858), HPLC grade acetonitrile (34851), DMSO (D8418), formic acid 
(5330020050) and hesperidin (PubChem CID: 174) were purchased from Sigma-Aldrich. The 
supplier for Narirutin (PubChem CID: 174) was Clearsynth Labs Ltd (Mumbai, India). 
FxCycle™ PI/RNase Staining Solution (F10797), Click-iT® EdU Alexa Fluor® 488 Flow 
Cytometry Assay Kit (C10425), SYTOX™ AADvanced™ Dead Cell Stain (S10349), 
PrestoBlue™ Cell Viability Reagent (A13261) and all cell culture supplies were from Life 
Technologies Gibco (Darmstadt, Germany).  
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3.2.2 Preparation of extract 
Citrus sinensis L. fruit was purchased from the local store and washed with tap water before the 
peel was collected. The peel was dried in a vacuum oven to remove moisture content and the 
dried peel was ground with a Nutribullet blender. Dried powder (20 gram) was soaked in 200 mL 
of a solvent such as MilliQ water or ethyl acetate: hexane (50:50, v/v) for 24 h at room 
temperature with continuous stirring. After 24 h, the solvent was collected, filtered using 
Whatman No.1 filter paper and dried using either rotary evaporator or freeze drier to remove 
hexane and aqueous solution, respectively. The dry residues obtained from ethyl acetate: hexane 
extract and water extract were dissolved in DMSO and MilliQ water, respectively. The ethyl 
acetate: hexane extract was labelled as hexane extract. DMSO and MilliQ water without extract 
were used as vehicle for control samples.    
 
3.2.3 Cell lines and synchronization at quiescence 
Bone metastasized prostate cancer cells (PC-3), lymph node metastasized prostate cancer cells 
(LNCaP) and human dermal fibroblast (GM3348) cells were obtained from American Type 
Culture Collection (Rockville, MD). GM3348 cells were cultured in complete medium 
containing Minimum Essential Medium (Gibco, 12571063) with 10% of fetal bovine serum 
(Gibco, 16000036) and 1% of Penicillin-Streptomycin (5000 U/mL). The prostate cells were 
cultured in RPMI 1640 (Gilco, New York) supplemented with 10% fetal calf serum (Gilco, New 
York) in a humidified cell incubator at 37°C in the presence of 5% CO2. An exponential growing 
PC-3 and LNCaP cells were used only for cell viability test. For other experiments, quiescent 
cells were prepared according to the method reported by Xi, Yao et al. (2016) with small 
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modifications. Briefly, exponential growing PC-3 cells were seeded in T75 flask and allowed to 
grow in complete medium until it reaches complete confluence. Thereafter, the medium was 
replaced with fresh complete medium and the confluence was maintained for three days. 
Meanwhile, for LNCaP cells, the exponential growing cells were seeded directly to the six-well 
plate and allowed to grow until it reached 60–70% confluence. Then, the LNCaP cells were 
cultured in serum-free medium for seven days. Cell cycle re-entry was rendered by passaging the 
PC-3 cells at low density or by serum replenishment for LNCaP cells.  
 
3.2.4 Cell viability assay 
Exponential growing LNCaP (1  105 cells/well) and PC-3 (7  104 cells/well) cells were seeded 
in 96-well plates and cultured in complete medium. After 24 h, the medium was replaced with a 
new complete medium containing different concentrations of CPE. At the end of treatment, the 
medium in the well was replaced with 100 µL of complete medium containing 5% of presto blue 
reagent (Carlsbad, CA). Fluorescence intensity was measured after 30 minutes using microplate 
reader SpectraMax Plus (Molecular Devices, CA) at an excitation of 540 nm and emission of 
590 nm. Blank is absorbance intensity of 100 µL of complete medium containing 5% of presto 
blue reagent only and control is absorbance intensity of cells exposed to the same volumes of 
water or DMSO applied when cells are exposed to the CPE. Inhibitory rate of cell proliferation 
was calculated using the following formula: Inhibitory rate (%) = (Sample-Blank) × 100% / 
(Control-Blank).  
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3.2.5 Cell cycle analysis 
Quiescent LNCaP (1  105 cells/well) and PC-3 (1.5  105 cells/well) were cultured in complete 
medium containing CPE at IC50 concentration in a six-well plate. For control cells, same 
volumes of water or DMSO were applied to the cells. The cells were harvested, fixed with ice-
cold 70% ethanol and stored at 4°C. Prior to flow analysis, the cells were washed with phosphate 
buffer solution (PBS) and stained with FxCycle™ PI/RNAse Solution. DNA content was 
measured at excitation of 488 nm and emission of 690 nm using a FACS Canto II flow cytometer 
equipped with BD FACSDiva™ software (BD Biosciences). To differentiate G0 cells from G1 
cells, the fixed cells were stained with 2 μg/ml of Hoechst 33258 in PBS at 37 °C for 45 min and 
followed by Pyronin Y at 4 μg/ml for 15 min (Xi, Yao et al. 2016). The cells were measured with 
flow cytometer at 350 nm Ex/450 nm Em for Hoechst 33258 and 488 nm Em/ 585 nm Em for 
Pyronin Y. 
      
3.2.6 DNA synthesis assay 
Approximately 1  105 cells/well of quiescent PC-3 cells were cultured in complete medium 
containing CPE at IC50 concentration in a six-well plate. For control cells, same volumes of 
water or DMSO were applied to the cells. PC-3 cells were harvested after 24 and 48 h. The 
newly synthesized DNA was determined using Click-iT® EdU Alexa Fluor® 488 Flow 
Cytometry Assay Kit and SYTOX™ AADvanced™ Dead Cell Stain in the presence of RNase. 
The assay was performed according to the manufacturer’s protocol. The cells were analysed with 
flow cytometer at an excitation of 488 nm and emission of 530 nm and 670 nm.  
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3.2.7 Apoptosis analysis   
Apoptosis cells were determined using a FITC Annexin-V apoptosis assay according to the 
manufacturer’s protocol. Approximately 150000 of quiescent PC-3 cells were cultured in 
complete medium containing CPE at IC50 concentration in a six-well plate. For control cells, 
same volumes of water or DMSO were applied to the cells. At the end of treatment, the cells 
were harvested, washed with PBS and suspended in 100 µL of Annexin-V binding buffer, 
followed by staining with of 5 µL of Annexin V FITC Conjugate and 10 µL of propidium iodide 
solution for 15 min in the dark. With flow cytometer, the cells were excited at 488 nm and 
measured the emission at 530 and 580 nm.   
  
3.2.8 Flavonoid quantitation 
The HPLC system consisted of Shimadzu DGA-20A vacuum degasser, two LC-20AD pumps, 
SIL-20A auto-sampler, CTO-20A column oven, SPD-M20A diode array detector and CBM-20A 
system controller was used for extract profiling and flavonoid quantitation. A 10 μL of extract 
was separated using a Phenomenex Synergi Fusion column (250 × 4.6 mm, 4 μm) at a flow rate 
of 1.0 mL/min with a temperature of 30°C. The mobile phase was acetonitrile and water 
containing 0.1% formic acid. The concentration of acetonitrile in the mobile phase was gradually 
increased from 20% to 30% in 10 minutes, then ramped to 70% over 5 minutes and decreased to 
20% in 5 minutes. The bioactive compounds in extracts were detected at 230 nm. For flavonoid 
quantitation in the extract, a calibration curve constructed using standard flavonoid solution in 
DMSO.  
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3.2.9 Statistical Analysis 
IBM SPSS Statistics software version 24 was used for statistical analysis. Student's two-tailed t-
test was used for comparison between two different groups and ANOVA analysis was used with 
Tukey multiple comparison test for multiple comparisons. All P-values <0.05 were considered 
statistically significant. 
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3.3 Results 
3.3.1 Toxicity of extract on prostate cancer cells 
Both CPEs obtained from extraction with water and hexane solvent were tested for cell viability 
on exponentially growing PC-3 and LNCaP cells for a period of 48 h. Figure 3.1 shows the 
images of proliferating PC-3 and LNCaP cells that were used for cell viability assay. The cell 
viability of extracts on PC-3 cells and LNCaP cells were shown in Figure 3.2 and Figure 3.3, 
respectively. Water extract in the range of 6.0-17.9 mg/mL and hexane extract in the range of 
12.5-400.0 µg/mL showed cell viability inhibitory effect dose-dependently on these cancer lines. 
The IC50 (mg/mL) at 48 h for water extract and hexane extract on PC-3 cells was 13.7±0.2 and 
0.156±0.016, respectively, while for LNCaP cells was 13.5±0.7 and 0.081±0.018, respectively. 
The IC50 values clearly illuminated that hexane extract was more effective than water extract in 
reducing viability of prostate cancer cells. This result also indicated both CPEs were efficient in 
reducing cell viability and impeding cell growth in both cancer lines at different concentrations.  
  
Figure 3.1: Images of proliferating PC-3 (a) and LNCaP cells (b) were assessed by Nikon 
Eclipse TS100 inverted microscope.  
a b 
500 µm 500 µm 
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a) PC-3 cells, water extract  
 
b)  PC-3 cells, hexane extract 
 
Figure 3.2: Water (a) and hexane (b) extracts decrease cell viability of PC-3 prostate cancer 
cells. Results are presented as the mean ± SD of three independent experiments (n=3).                  
* indicates no significant difference compared to control at p <0.05.   
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a) LNCaP cells, water extract  
 
b)  LNCaP cells, hexane extract 
 
Figure 3.3: Water (a) and hexane (b) extracts decrease cell viability of LNCaP prostate cancer 
cells. Results are presented as the mean ± SD of three independent experiments (n=3).                   
* indicates no significant difference compared to control at p < 0.05.   
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3.3.2 Ability of extract in halting the cell cycle re-entry of prostate cancer cells 
To evaluate the ability of CPE in arresting the quiescent cells at the G0 phase, the quiescent 
prostate cancer cells were allowed to enter the cell cycle in the presence of CPE at IC50 
concentration. Upon released from quiescence, the PC-3 cells were analysed at every 8 h interval 
for 48 h and LNCaP cells were analysed at every 24 h interval for 120 h. Figure 3.4 shows the 
proliferating cells before induced to quiescence and the quiescent cells that were used for the 
experiment. Figure 3.5 and Figure 3.6 show the PC-3 and LNCaP cells incubated in the presence 
of extract at different h. 
 
 
 
  
Figure 3.4: Images of proliferating PC-3 cells (a), quiescent PC-3 cells after 3 days of contact 
inhibition (b), proliferating LNCaP cells (c) and quiescent LNCaP cells after cultured in serum-
free culture medium for 7 days (d) were assessed by Nikon Eclipse TS100 inverted microscope.   
a 
d c 
b 
500 µm 500 µm 
500 µm 500 µm 
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Figure 3.5: Images of quiescent PC-3 cells grown in water or hexane extract at different hours 
upon released from quiescence were taken by Nikon Eclipse TS100 inverted microscope.  
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Figure 3.6: Images of quiescent LNCaP cells incubated in water or hexane extract at different 
hours upon released from quiescence were assessed by Nikon Eclipse TS100 inverted 
microscope. 
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Cell cycle profile of these cells was analysed by measuring propidium iodide-stained DNA with 
flow cytometry. As shown in Figure 3.7 and Figure 3.8, when the proliferating PC-3 and LNCaP 
cells were forced to enter quiescence, the number of cells in G0/G1 phase was increased, while S 
and G2/M phases were decreased. Compared to proliferating cells, both quiescent PC-3 and 
LNCaP cells differed in the number of cells at the G0/G1 phase by 24% and 17%, respectively. 
Upon released from quiescence, the cells re-entered the cell cycle and a reduction in the 
proportion of cells in the G0/G1 cells and increased of  S and G2/M in control PC-3 and LNCaP 
cells. PC-3 cells were re-entered cell cycle more rapidly than LNCaP cells, after nearly 16 h 
following release from quiescence. The difference between PC-3 cell treated with water extract 
and control at 48 h in term of the number of cells at the G0/G1 phase was 18%, whereas for 
hexane extract was 2%. For LNCaP cells, the difference in the number of cells at G0/G1 at 120 h 
was 12% for water extract, while for hexane extract was 3%. This significant difference in the 
number of cells at the G0/G1 phase clearly indicated the effectiveness of water extract in halting 
cell cycle re-entry of PC-3 and LNCaP cells (p < 0.05). In contrast, the hexane extract exhibited 
negligible cell cycle inhibitory activity in both cell lines.  
The propidium iodide staining method indicated the CPE arrested the cells at G0/G1 and it was 
unclear whether the cells progressed from G0 to G1. It has been reported that G0 cells contain a 
lower amount of RNA than G1 cells due to the low gene transcription (Gao, Ouyang et al. 2004). 
Thus, a double staining method using Hoechst 33258 for DNA content and Pyronin Y for RNA 
content was used to differentiate the G0 and G1 cells for samples at 24 and 48 h. As shown in 
Figure 3.9, quiescent PC-3 and LNCaP cells have higher percentages of G0 cells than their 
respective proliferating cells, which was in agreement with a previous study (Xi, Yao et al. 
2016). A reduction in the percentage of G0 cells upon release from quiescence was observed in 
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control PC-3 and LNCaP cells. During cell cycle re-entry, the PC-3 and LNCaP cells treated 
with hexane extract did not show any difference with their respective control cells. A reduction 
in the G0 population by 21% (vs. 22% for control) for PC-3 cells at 48 h, whereas by 15% (vs. 
14% for control) for LNCaP cells at 96 h were observed for hexane extract upon released from 
quiescence phase. However, no significant reduction in the G0 population was observed in both 
PC-3 and LNCaP cells treated with water extract with their control (p < 0.05). The G0 
population was reduced by 1% for water extract treated PC-3 cells at 48 h. In contrast, water 
extract treated LNCaP cells showed a higher amount of G0 cells by 8% than the quiescent cells. 
These results suggested that water extract is capable in inhibiting cell cycle re-entry of quiescent 
prostate cancer cells by preserving the cells in G0 phase.    
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a) PC-3 cells, water extract        b) PC-3 cells, hexane extract 
 
 
        
Figure 3.7: Cell cycle profile for PC-3 cells treated with hexane (a) and water (b) extract upon release from quiescence. Active 
(control cells: non-quiescent cells). Quiescent (quiescent cells: PC-3 after contact inhibition for 3 days). Data are expressed as the 
mean±S.D of three independent experiments compared with non-quiescent controls (Control; 
###
P < 0.001) or water or DMSO vehicle 
control cells at each time point (*P < 0.05, **P < 0.01, ***P < 0.001). 
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a) LNCaP cells, water extract        b) LNCaP cells, hexane extract                  
        
Figure 3.8: Cell cycle profile for LNCaP cells treated with hexane (c) and water (d) extract upon release from quiescence. Active 
(control cells: non-quiescent cells). Quiescent (quiescent cells: LNCaP after serum withdrawal for 7 days). Data are expressed as the 
mean±S.D of three independent experiments compared with non-quiescent controls (Control; 
##
P < 0.01, 
###
P < 0.001) or water or 
DMSO vehicle control cells at each time point (*P < 0.05, **P < 0.01, ***P < 0.001). 
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a) PC-3, water extract  b) PC-3, hexane extract 
  
c) LNCaP, water extract  d) LNCaP, hexane extract 
  
Figure 3.9: Representative flow cytometer images showing proportion of G0 cells in proliferating, 
quiescent, and during cell cycle re-entry with CPE at IC50 or control at indicated h for PC-3 cells 
treated with water (a) and hexane (b) extract, while for LNCaP cells treated with water (c) and hexane 
(d) extract. Proliferating (control cells: non-quiescent cells). Quiescent (quiescent cells: LNCaP after 
serum withdrawal for 7 days or PC-3 after contact inhibition for 3 days). 
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3.3.3 Effect of extract on DNA synthesis rate of prostate cancer cells 
Effect of CPE at IC50 concentration on DNA synthesis rate of quiescent PC-3 cells upon released 
from quiescence was measured using Click-iT EdU incorporation assay.  The DNA synthesis 
rate was directly proportional to the amount of EdU incorporated by the cells. The result in 
Figure 3.10 shows the percentage of incorporated EdU in PC-3 cell treated with CPE and control 
at 24 and 48 h. Percentage of cells with EdU marker for control PC-3 cells that were either 
treated with water or DMSO was in the range of 16.5 to 18.6%, whereas for CPEs was in the 
range of 1.7 to 7.0%. Hexane extract showed a significant reduction in cell proliferation as 
indicated by the lower EdU incorporation by 58 and 71% compared to control at 24 and 48 h, 
respectively (p < 0.05). Whereas for the water extract-treated cells, the EdU incorporation was 
lower by 89% and 86% than control at 24 and 48 h, respectively (p < 0.05). Results from the 
EdU incorporation assay illustrated that both CPEs significantly decreased cell proliferation in 
PC-3 cells with the water extract possesses a stronger proliferation inhibitory effect than hexane 
extract. Representative flow cytometry plots of cells at S phase with incorporated EdU marker 
are shown in Figure 3.11. 
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Figure 3.10: Percentage of EdU incorporation on PC-3 cells cultured with water (a) and hexane 
(b) extract at 24 and 48 h upon release from quiescence. Data are expressed as the mean±S.D of 
three independent experiments (b). *P < 0.05, **P < 0.01 vs. control. 
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a) PC-3, water extract  b) PC-3, hexane extract 
  
Figure 3.11: Representative flow cytometry plots for the PC-3 cells with EdU incorporation cultured with water extract (a) and 
hexane (b) extract at 24 and 48 h upon release from quiescence.  
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3.3.4 Apoptosis-inducing effect by extract on prostate cancer cells 
CPEs ability in inducing apoptosis on quiescent PC-3 cells upon released from quiescence was 
determined using FITC Annexin-V apoptosis assay. Numbers of viable, necrotic, early apoptotic, 
and apoptotic cells at 24 and 48 h were shown in Figure 3.12. A significant difference in the 
number of apoptotic cells between control and hexane treated cells at 24 and 48 h (p < 0.05) was 
observed, which suggesting apoptosis-inducing effect of hexane extract on PC-3 cells. The 
difference in the number of apoptotic cells was nearly two-fold. In contrast, the apoptotic effect 
was not observed in cells treated with water extract. Moreover, compared to control a negligible 
variation in the number of viable, necrosis and early apoptosis cells were observed for the cell 
treated with water extract. Similarly, the hexane extract showed no difference for early apoptosis 
on PC-3 cells and it slightly increased the number of necrosis cells at 24 and 48 h.       
 
Figure 3.12: Percentages of viable, necrotic, early apoptotic, and apoptotic cells in quiescent 
PC-3 population exposed to extracts at 24 and 48 h. Data are expressed as the mean±S.D. of 
three independent experiments. * indicates a significant difference from control, p < 0.05. 
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3.3.5 Extract profiling and flavonoid quantitation 
The two CPEs obtained using different extraction solvents were expected to have variation in the 
bioactive compound content. The composition of extracted bioactive compounds in hexane and 
water extracts was profiled using reverse-phase HPLC. The two CPEs used in this study have 
different compound profiles as shown in Figure 3.13. Water extract contains more peaks at a 
higher intensity than the hexane extract. This high number of peaks indicates the water solvent 
extracts a range of various water-soluble compounds from the citrus peel. As expected, hexane 
extract contained more non-polar compounds as observed at 15 to 17 minute, which could be the 
polymethoxyflavones. Two major peaks in water extract were identified to be narirutin and 
hesperidin using standard samples. Concentrations of narirutin and hesperidin in water extract 
were 400 and 514 µg/mL, respectively as shown in Table 3.1.  
 
Figure 3.13: HPLC chromatogram at UV 230 nm of standards, water extract and hexane extract. 
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Table 3.1: Concentration of flavonoids in extracts  
Sample  
µg/mL 
Narirutin Hesperidin 
Water  400.00 ± 6.57 (50) 513.74 ± 5.43 (64) 
Hexane  7.29 ± 0.02 (1.5) 12.14 ± 0.15 (2.5) 
n=3, mean ± std,  
Value in bracket denotes the calculated concentration of the compound in extract exposed to the 
cells at IC50 value.  
 
3.3.6 Effect of hesperidin and narirutin on cell cycle of prostate cancer    
Hesperidin and narirutin were the prominent compounds in water extract and it was presumed 
that these compounds could contribute to the observed cell cycle inhibitory activity. The 
quiescent PC-3 cells were allowed to enter cell cycle in the presence of hesperidin or narirutin in 
the range of 18.75-300 µg/mL. An increase in the numbers of cells in S and G2/M phases was 
observed when the quiescent PC-3 cells were released in the presence of hesperidin or narirutin 
as depicted in Figure 3.14. The quiescent cells entered cell cycle upon release from quiescence 
and it indicated that these flavonoids were not directly responsible for the cell cycle re-entry 
inhibitory activity. Hesperidin at 300 µg/mL killed almost all of the PC-3 cells and only about 
half of these cells survived at 150 µg/mL. However, this observation was not noted for narirutin.   
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a) Hesperidin 
 
 
 
b) Narirutin 
 
 
Figure 3.14: Cell cycle profile of PC-3 cells treated with hesperidin (a) and narirutin (b) at 
different concentrations (µg/mL) upon release from quiescence. Data are expressed as the 
mean±S.D of one representative experiment. 
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3.3.7 Influence of pH of water extract on the cell cycle inhibitory effect       
Addition of citrus peel extract to the cell culture medium lowered the pH of the cell culture 
medium. Thus, effect of pH of water extract on the PC-3 cell cycle re-entry inhibitory activity 
was determined by comparing the cell cycle of the cells cultured in culture medium containing 
extract (as it is) with cells cultured in neutralized (pH 7.4) culture medium containing extract 
using sodium hydroxide. The cells were cultured at IC50 of water extract for 24 h. There was no 
increment in the numbers of cells in S and G2/M phases for cell cultured at pH 6.4 and 7.4 
(Figure 3.15). Number of PC-3 cells in each phase at pH 6.4 and 7.4 after 24 h incubation was 
not significantly different to each other (p <  0.05), indicating the effect was induced by the 
compounds in the extract. The cells were tolerable to reduced pH at the IC50 of water extract.  
  
Figure 3.15: Cell cycle profile of PC-3 cells treated with water extract at different pH upon 
release from quiescence. Data are expressed as the mean±S.D of one representative experiment 
(n=3). 
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3.3.8 Water extract toxicity on the fibroblast cells  
Water extract at different concentrations up to 23.8 mg/mL was evaluated on exponentially 
growing normal GM3348 fibroblast cells for the cell viability. Percentage of live cells after 
exposure to water extract at different concentrations for 24, 48 and 72 h was measured with 
PrestoBlue® cell viability assay. Figure 3.16 (a) shows the effect of water extract at different 
concentrations on the cell viability of fibroblast cells. Number of survived cells after cultured in 
extract dose-dependently decreased and also with an increase in incubation duration. Water 
extract significantly inhibited viability of fibroblast cells at concentration above 17.9 mg/mL at 
24 h and 11.9 mg/mL at 48 h compared to control (p < 0.05). It is also noted that increment in 
the concentration of extract reduced the pH of culture medium. Thus, to eliminate the effect of 
pH of culture medium on the cell viability of cells, the extract in culture medium was neutralized 
with sodium hydroxide to pH around 7.4. The extract at neutral pH did not significantly inhibit 
the fibroblast cells up to 23.8 mg/mL at 24 h. However, a significant inhibitory effect was 
observed for concentration above 17.9 mg/mL at 48 h (Figure 3.16 (b)). The pH of culture 
medium has a significant effect on the fibroblast cell viability and this result concluded that the 
fibroblast cells are sensitive to the pH.   
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a) GM3348 cell, water extract without neutralization step 
 
 
b) GM3348 cell, water extract with neutralization step  
 
Figure 3.16: Water extract without neutralization step (a) and with neutralization step (b)  
decrease cell viability of GM3348 fibroblast cells. Results are presented as the mean ± SD of two 
independent experiments (n=6). * indicates significant difference than control (0 mg/mL) at p < 
0.05.   
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3.3.9 Changes in cell cycle profile of proliferating prostate cancer cells by water extract  
The water extract was also tested on the actively proliferating PC-3 cells to investigate the phase 
of the cell cycle that the water extract could arrest. The active cells were exposed to extract at 
different concentrations up to 72 h. As illustrated in Figure 3.17, the cells cultured without 
extract showed the number of cells increased in G1 phase and decreased in G2/M with the 
increase in incubation time. However, a reduction in the increment in the number of cells at the 
G1 phase was observed for cell cultured with extract at a concentration of 6 mg/mL. Meanwhile, 
for cells cultured in the extract at 8.9, 11.9 and 14.9 mg/mL, the number of cells at the G1 phase 
was almost similar or slightly reduced. The cells cultured with extract at 17.9 mg/mL showed the 
lowest amount of cells at the G1 phase compared to the other samples. No change in the number 
of cells at any cell cycle phases was observed for cells cultured at this concentration. Not only 
that, the number of cells at G2/M was increased with the increase of concentration and 
incubation period. It can be concluded that the water extract reduced the progression of cells 
from G0/G11 phase to S phase.    
 
Figure 3.17: Cell cycle profile for actively proliferating PC-3 cells treated with water.  Data 
are expressed as the mean±S.D of one technical experiment (n=3).  
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3.4 Discussion   
In this study, two different solvents, water and hexane, were used to extract a different range of 
bioactive compounds from the citrus peel. Both CPEs dose-dependently reduced cell viability of 
proliferating PC-3 and LNCaP cells. Hexane extract showed stronger cell viability inhibitory 
effect than the water extract on these cells. This result is in agreement with previous studies 
where the hexane fraction showed stronger cell viability inhibitory effect than water fraction on 
different cancer cells such as U937 leukaemia and HT-29 colon cells (Hirata, Fujii et al. 2009, 
Lim, Moon et al. 2009). The difference in the IC50 values between two CPEs shows the variation 
in the composition of extract. The high IC50 values of water extract was due to the ability of the 
water solvent that extracts various types of hydrophilic compounds such as sugars, 
polysaccharides and proteins.  
The ability of extract to prevent cell cycle re-entry was tested by allowing the quiescent cells to 
re-enter cell cycle in the presence of extract. It is interesting to note that only water extract was 
able to prevent the PC-3 and LNCaP cells from entering S phase from G0/G1 phase upon 
released from quiescence. Induction of cell cycle re-entry upon release from quiescence involves 
a rapid up-regulation of mRNA for various proteins, which can be measured with RNA content. 
Water extract maintains the cells in quiescence as a higher amount of cells in G0 phase was 
found for treated than the control. The low incorporation of EdU in water extract-treated cells 
further verifies that the PC-3 cells were in quiescence and did not proliferate. These results also 
revealed that the hexane extract suppressed the proliferation of PC-3 cells and failed to prevent 
the from re-entering the cell cycle upon released from quiescence. This finding is in agreement 
with our results with cell viability and cell cycle analysis.     
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It is reported that CPEs and the bioactive compounds derived from the extracts exhibit apoptosis 
in many cancer lines including colon, leukaemia, lung and breast (Cirmi, Ferlazzo et al. 2016). In 
this study, the water extract showed no apoptotic effect on quiescent PC-3 cells in contrast to the 
observed mild apoptotic effect by the hexane extract on quiescent PC-3 cells. Most likely 
increasing the extract concentration could lead to significant apoptosis effect. The cell cycle and 
apoptosis results demonstrated that the extract reduced the cell viability mainly by suppressing 
cell proliferation rather than inducing apoptosis. Moreover, this finding also suggested that the 
hexane extract contains apoptosis-inducing compounds in higher amount or the compounds are 
more toxic than those present in water extract. It was hypothesised that the LNCaP cells could 
have a similar response to the EdU incorporation and apoptosis to both extracts.  It was also 
noted that LNCaP cells treated with water extract had high amount dying cells, which probably 
due to the apoptosis.  
The above results show that the water extract is effective than hexane extract in preventing the 
quiescent prostate cancer cells from re-entering the cell cycle. It was presumed that the presence 
of high amount of hesperidin and narirutin in water extract was responsible for the observed cell 
cycle re-entry inhibitory activity. When tested on quiescent PC-3 cells, these two flavonoids 
showed no effect in halting cell cycle re-entry upon released from quiescence. These flavonoids 
also did not arrest the quiescent PC-3 cells at G2/M phases; although, flavonoids are known for 
G2/M cell cycle arrest (Ren, Qiao et al. 2003). In one study, PC-3 cells exhibited negligible 
proliferation inhibition response to the hesperidin at 61 µg/mL (Lee, Wilson et al. 2010). In this 
study, a significant amount of dead cells was observed for PC-3 cells treated with hesperidin at 
150 µg/mL. Moreover, the hesperidin at 300 µg/mL killed completely the PC-3 cells whereas 
narirutin showed no toxicity effect, indicating a significant role of the methoxy group at B 
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aromatic ring in hesperidin structure in inducing strong toxicity effect. As reported previously a 
small difference in the flavonoid structure could have a significant anticancer effect (Manthey 
and Guthrie 2002, Qiu, Dong et al. 2010).  
This result shed light on the presence of other bioactive compounds in the extract that play a key 
role in cell cycle re-entry inhibitory activity. Most likely the synergic effect of the combination 
of different compounds such as flavonoids led to observing bioactivity for keeping the cancer 
cell in the dormant phase. It was suggested that single compound may not show the similar effect 
as the crude extract or combination of few compounds as the single compound may not behave 
the same way as the compound in whole foods (Liu 2004). This concept has encouraged the use 
of complex mixtures of bioactive substances such as crude extract rather than isolated individual 
compound for maximum biological activity. In this study, the water extract showed low or no 
toxicity on normal fibroblast cells compared to prostate cancer cells, which indicates the 
selectivity of the extract in targeting cancer cells. Moreover, CPE has been reported to have no 
toxicity effect in normal RWPE-1 cells (Kim, Lee et al. 2017) and the in-vivo experiments 
showed no adverse effect on the organs of mice treated with CPE (Lai, Li et al. 2013b, Kim, Lee 
et al. 2017). This study provided information that water extract of citrus peel that is rich in 
bioactive compounds could be a good source in preventing quiescent cancer cell from entering 
the cell cycle. Moreover, the citrus peel that is currently treated as landfill will be utilized in a 
better way by converting it into food supplements and nutraceutical products. 
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3.5 Conclusion 
In conclusion, this study demonstrated that water extract from citrus peel was effective in 
preventing quiescent prostate cancer cells from re-entering cell cycle when tested on an 
established in-vitro model of prostate cancer quiescent cells. Not only that, the water extract was 
also exhibited stronger proliferation inhibitory effect on prostate cancer cells than normal 
fibroblast cells. Even though more studies are required to identify the potent bioactive compound 
to verify this finding, this study provided an initial finding to encourage the use of whole citrus 
peel extract for post-therapy prostate cancer patients.  
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4 A new cell cycle inhibitor, citric acid, from 
water extract of citrus peel. 
 
4.1 Introduction    
Cell cycle is a vital mechanism of a cell in controlling cell division and progression. A cell is 
progressed in a highly coordinated event through four distinct phases (G0/G1, S, G2 and M) of 
the cell cycle (Schwartz and Shah 2005, Otto and Sicinski 2017). Dysregulation of this process 
could lead to a continuous cell cycle division, which is regarded as a fundamental character for 
cancer (Schwartz and Shah 2005, Otto and Sicinski 2017). Therefore, modulation of cell cycle 
proteins and signalling pathways to halt the cell cycle progression is a promising strategy against 
cancer (Vermeulen, Van Bockstaele et al. 2003, Schwartz and Shah 2005).  
Flavopiridol, Palbociclib and Volasertib are some of the developed new anticancer drugs that 
specifically target the cell cycle modulator proteins. However, many modern chemotherapy 
drugs show low efficacy and non-specific toxicity in targeting cancer cells, while are resulting in 
some undesirable side health effects. These limitations have encouraged the search for anticancer 
compounds from natural sources  (Newman and Cragg 2016). A review of the anticancer drugs 
showed about 49% of small molecule-based anticancer drugs that are either natural products or 
directly derived therefrom were approved by the US Food and Drug Administration to the 
market between 1940 and 2014 (Newman and Cragg 2016). It clearly indicates that nature is a 
rich source for novel drug discovery. 
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Citrus contains considerable amounts of biologically active compounds such as flavonoids, 
limonoids, coumarins, phenolic acids, terpenoids, and carotenoids (Yu, Wang et al. 2005, Zou, 
Xi et al. 2016), along with many other unknown bioactive components. The various biological 
effects exhibited by citrus are mainly due to the activity of either individual or interaction of 
various bioactive compounds present in citrus (Liu 2004). Citrus extracts have been reported to 
arrest various lines of cancer cells at G0/G1 or G2/M phases (Cirmi, Ferlazzo et al. 2016). In the 
previous study, citrus peel extract (CPE) was shown to exhibit anticancer activity by inhibiting 
cell cycle re-entry on quiescent prostate cancer. It was hypothesized from that study that one or 
more compounds in CPE could contribute to the observed cell cycle re-entry inhibitory activity. 
To the best of our knowledge, no information on the active components associated with cell 
cycle re-entry inhibitory activity in citrus is available. Given the rich nature of citrus, the 
isolation and identification of bioactive compounds from citrus have a high practical value. Thus, 
the aim of this chapter was to isolate and identify the potent compounds with cell cycle re-entry 
inhibitory activity from citrus peel.  
 
4.2 Materials and methods 
4.2.1 Chemicals and reagents 
HPLC grade acetonitrile (34851), hexane (270504), ethyl acetate (34858), DMSO (D8418), 
trifluoroacetic acid (T6508) and were obtained from Sigma-Aldrich. PrestoBlue™ Cell Viability 
Reagent (A13261), FxCycle™ PI/RNase Staining Solution (F10797), and all cell culture 
supplies were from Life Technologies Gibco (Darmstadt, Germany). 
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4.2.2 Preparation of extract   
The water extract was prepared as described in Section 3.2.2.  
 
4.2.3 Solvent-solvent fractionation 
Water extract of citrus peel was fractionated using conventional solvent-solvent extraction 
technique. A 10 mL of water extract was extracted serially with hexane (10 mL × 2) and ethyl 
acetate (10 mL × 2). The hexane, ethyl acetate and water residue fractions were dried in a 
vacuum oven until complete dryness. The dried extracts were dissolved with 10 mL of phosphate 
buffer solution to achieve the initial concentration. The water extract and the fractions obtained 
from water extract were tested on the PC-3 cells.    
 
4.2.4 Preparative HPLC 
Preparative LC separation was carried out on a Waters 600 controller equipped with Waters 600 
binary pump, Waters 2487 UV detector and Waters Fraction Collectors III. The separation was 
carried out on a Waters Sunfire C18 OBD (19 mm × 150 mm, 5 μm) at a flow rate of 7 mL/min 
with a mobile phase of water and acetonitrile containing 0.1% trifluoroacetic acid. The 
concentration of acetonitrile in water was maintained at 0% for 1 min and then increased 
gradient to 100% over 60 min before returned to 0% in 5 minutes. For single compound 
isolation, the gradient of acetonitrile from 0% to 100% was extended over 2 h. The absorbance 
was detected at 230 nm. Collected fractions were dried under reduced pressure, dissolved in 
water to the original concentration. 
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4.2.5 Cell culture 
Prostate cancer (PC-3) and human dermal fibroblast (GM3348) cells were cultured as described 
in Section 3.2.3. Meanwhile, normal prostate epithelial (RWPE-1) cells obtained from the 
American Type Culture Collection (Rockville, MD). RWPE-1 cells were cultured in the 
complete medium of keratinocyte serum-free medium (Gibco, 17005042). The cells were grown 
in a humidified cell incubator at 37°C in the presence of 5% CO2. 
 
4.2.6 Cell viability assay 
Exponential growing PC-3 (7000 cells/well) cells, RWPE-1 (6000 cells) and GM3348 (2500 
cells/well) were seeded in 96-well plates in complete medium. After 24 h, the medium was 
replaced with a new complete medium containing different concentrations of 
extract/fraction/citric acid. The pH of culture medium containing citric acid was neutralized with 
sodium hydroxide to pH 7.4 before adding to the cells. The cell viability was measured as 
described in section 3.2.4.  
 
4.2.7 Cell cycle analysis 
Cell cycle analysis was performed as described in section 3.2.5.  
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4.2.8 Structure elucidation 
The isolated compound was identified by comparing the spectral data of mass spectrometry, 
nuclear magnetic resonance (NMR), and Fourier transform infrared (FTIR) with the 
commercially available standard. For mass spectrometry, Bruker amaZon SL quadrupole ion trap 
mass spectrometer equipment with atmospheric pressure chemical ionization (APCI) ion source 
was used. Mass range of m/z of 150–1000 was used for a full scan of the mass spectra in 
negative ion mode. The 1H-NMR spectra of the compound in D2O was recorded in a Bruker 
Avance III 600 MHz spectrometer operating at 600 MHz. The chemical shifts are expressed 
in δ (parts per million) and the coupling constants (J) in Hz. IR spectra were recorded with a 
Nicolet 6700 FTIR spectrometer in the range 400–4000 cm-1 from the average of 64 scans. 
 
4.2.9 Statistical Analysis 
IBM SPSS Statistics software version 24 was used for statistical analysis. Student's two-tailed t-
test was used for comparison between two different groups and ANOVA analysis was used with 
Tukey multiple comparison test for multiple comparisons. All P-values <0.05 were considered 
statistically significant. 
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4.3 Results 
4.3.1 Effect of different fractions of water extract on cell cycle re-entry inhibition  
Different fractions of water extract obtained using the solvent-solvent extraction method was 
tested on quiescent PC-3 cells. These quiescent cells were induced to re-enter cell cycle by re-
plating at low density with or without extract. As shown in Figure 4.1, the control cells re-
entered cell cycle upon release from quiescence where the number of cells at G0/G1 phase was 
reduced from 87% to 71% at 24 h and 66% at 48 h. In contrast, the PC-3 cells treated with water 
extract did not show any significant reduction at 24 h and reduced to 79% at 48 h (p < 0.05). 
Meanwhile, water fraction showed the strongest cell cycle re-entry inhibitory activity among the 
other fractions at the first 24 h. Number of cells at G0/G1 for water fraction at 24 h was 86%, 
whereas for other fractions were between 73-75%. At 48 h, cell cycle re-entry inhibitory activity 
was not observed for all fractions.  Numbers of cells at G0/G1 phase for cells treated with 
different fractions were in the range of 66-71%, which was insignificant compared to control 
(65.9%), p < 0.05. A reduction in the number of cells at G0/G1 was accompanied with an 
increase in the number of cells at S and G2/M phase when the quiescent cells entering the cell 
cycle. A similar observation was noted for all samples except the water extract and water fraction 
at 24 h. As the water fraction showed the highest cell cycle re-entry inhibitory activity, the 
compound(s) that are responsible for the observed biological were predicted to be hydrophilic 
compounds.   
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Figure 4.1: Cell cycle profile of PC-3 cells treated with extract and solvent-solvent extraction 
fractions of water extract upon release from quiescence. Control cells were exposed to same 
amount of water as the water extract and the fraction treated cells. Quiescent cells are PC-3 cells 
after contact inhibition for 3 days. Data are expressed as the mean±S.D of three independent 
experiments. *indicates a significant difference compared to control, p < 0.05. 
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Since water fraction showed the highest cell cycle re-entry inhibitory activity, the extract was 
subjected for separation using a preparative HPLC system equipped with a C18 column. The 
polar compound will elute out earlier from column than non-polar compound because the non-
polar compounds have a stronger chemical interaction with the material of the column. The 
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many major peaks indicating by the broad and tall peaks such as at 18 min and 24 min. The 
peaks at 36-40 min are more likely to be polymethoxyflavones based on the reported literature. 
The extract were fractionated into three fractions based on time where elute between 0-14 min 
represented fraction 1, elute between min 14-28 represented fraction 2 and elute between 28-42 
min represented fraction 3. 
 
 
Figure 4.2: Fractionation of water extract using a Sunfire OBS C18 HPLC preparative column at 
an UV wavelength of 230 nm. The fraction was collected at 14 minutes interval as indicated in 
the figure using fraction collector. 
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not decrease for the first 24 h compared to quiescent cells (p < 0.05). However, the inhibitory 
activity of the fraction reduced for the next 24 h, especially for fraction 2 and 3.  At 48 h, only 
fraction 1 showed strong significant inhibitory activity compared to control (p < 0.05) and this 
indicate that the potent compound presents in this elution region. The other two fractions still 
showed higher activity compared to control even at 48 h, indicating the fractions contained the 
cell cycle inhibitory compounds. However, due to the concentration factor, the fraction showed 
mild biological activity.  
 
 
Figure 4.3: Cell cycle profile of PC-3 cells treated with fractions of the extract obtained using 
preparative HPLC system upon release from quiescence. Quiescent cells are PC-3 cells after 
contact inhibition for 3 days. Data are expressed as the mean±S.D of representative one 
experiment. *indicates a significant difference compared to control, p < 0.05. 
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The fraction 1 that showed the highest inhibition was further fractionated with 2 minutes interval 
to identify the compounds (Figure 4.4). The process yielded six fractions and the fraction 
between min 10-12 showed the highest cell cycle re-entry inhibitory activity at 24 h and 48 h. It 
was also observed that at 48 h, the inhibitory effect of the fraction is not as strong as at 24 h. 
Fraction collected between min 10-12 contained five compounds and the compounds were 
collected and tested individually.  
 
 
Figure 4.4: Fractionation of fraction 1 using a Sunfire OBS C18 HPLC preparative column at an 
UV wavelength of 230 nm. The fraction was collected at every 2 minutes interval as indicated in 
the figure using fraction collector. 
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Only one compound out of five compounds in potent fraction was found to contribute to the 
inhibitory effect. As shown in Figure 4.5, the compound showed a significant inhibitory effect 
when tested on the quiescent PC-3 cells up to 48 h (p < 0.05).  Number of cells at G0/G1 
reduced from 87% to 85% at 24 h and to 83% at 48 h.  
 
Figure 4.5: Cell cycle profile of PC-3 cells treated with the isolated compound upon release 
from quiescence. Quiescent cells are PC-3 cells after contact inhibition for 3 days. Data are 
expressed as the mean±S.D of three independent experiments. *is used to indicate the significant 
difference compared to control, p < 0.05.  
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(Figure 4.6). The low molecular mass indicated that the compound was a small compound. 
However, the UV spectrum showed the compound was undetectable at 280 nm, thus eliminated 
the presence of benzene ring. To identify the functional group on the molecule, the compound 
was analysed with FTIR. The FTIR result showed the compound contained –OH and C=O 
functional groups (Figure 4.7). This is parallel with high solubility of the compound in water, 
low retention in C18 column and the no UV detection at 280 nm. Based on retention time and 
UV spectrum, citric acid standard showed the possible match. Figure 4.8 shows the 1H-NMR 
(600 MHz, CD3OD) of citric acid standard and isolated compound, δH: 6.17 (1H, d, J = 1.4 Hz, 
H-6), 6.38 (1H, s, H-8), 8.07 (1H, d, J = 8.7 Hz, H-2), 6.89 (1H, d, J = 8.7 Hz, H-3), 6.89 (1H, d, 
J = 8.7 Hz, H-5), 8.07(1H, d, J = 8.7 Hz, H-6). The NMR data is in agreement with the citric acid 
standard and the reported literature values. The structure of the isolated compound was identified 
as a citric acid (PubChem CID: 311): C6H8O7.  
 
Figure 4.6: APCI-MS spectra of the isolated compound. 
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Figure 4.7: FTIR spectrum of the isolated compound. 
 
 
Figure 4.8: 1H-NMR spectrum in D2O of the isolated compound and citric acid standard. 
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4.3.4 Citric acid toxicity on cancer and non-cancer cells 
Citric acid dose-dependently inhibited cell viability of PC-3 cells as the cell viability decreased 
with the increase of citric acid concentration when tested in the range of 0.125-1.25 mg/mL 
(Figure 4.9). Significant toxicity effect was observed at a concentration above 0.5 mg/mL with 
stronger cell viability inhibitory effect over prolonged exposure to citric acid.  Cell culture 
medium containing citric acid standard was neutralized to pH 7.4 with sodium hydroxide to 
remove the effect of pH on the cell viability.  
 
 
Figure 4.9: Cell viability effect of the citric acid standard on the PC-3 cells. Data are expressed 
as the mean±S.D of three independent experiments. * indicates a significant difference compared 
to control, p < 0.05. 
 
 
0
20
40
60
80
100
0.00 0.13 0.25 0.50 0.75 1.00 1.25
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
 
Concentration (mg/mL) 
Day 1 Day 2
* 
* 
* 
* 
* * 
* 
89 
 
Citric acid was also tested on the normal epithelial prostate (RWPE-1) cells for the cell viability 
effect. Citric acid showed cell viability inhibitory effect on the RWPE-1 cells as the number of 
cells decreased with the increase of citric acid concentration and the incubation duration. Citric 
acid with the concentration above 0.5 mg/mL in the medium was significantly inhibited cell 
growth compared to control. However, it can be seen that the effect of citric acid on the viability 
of RWPE-1 cells reduced at a concentration above 1 mg/mL.  The observed cell viability effect 
was due to the citric acid standard and not from the pH of culture medium as the culture medium 
was neutralized to pH 7.4 after the addition of citric acid standard. 
 
 
 
Figure 4.10: Cell viability effect of the citric acid standard on the RWPE-1 cells. Data are 
expressed as the mean±S.D of three independent experiments. * indicates significant difference 
compared to control, p < 0.05.  
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The comparison of the cell viability of PC-3 and RWPE-1 after 48 h of incubation with citric 
acid is shown in Figure 4.11. No significant difference in cell viability between both cells was 
observed at a concentration between 0-0.75 mg/mL (p < 0.05). However, citric acid significantly 
exhibited higher cell viability inhibitory effect on PC-3 cells than RWPE-1 cells at a 
concentration above 1 mg/mL (p < 0.05). The cell viability inhibitory effect at a concentration 
above 1 mg/mL on PC-3 cells by citric acid was more than one fold stronger compared on 
RWPE-1 cells. 
 
Figure 4.11: Cell viability effect of citric acid standard on the PC-3 and RWPE-1 cells. Data are 
expressed as the mean±S.D of three independent experiments. * indicates a significant difference 
compared to PC-3 cells at the same concentration, p < 0.05. ND, not determined.  
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Interestingly, citric acid in the range of 0.125-1.25 mg/mL showed an insignificant effect on the 
cell viability of human normal fibroblast GM3348 cells (Figure 4.12).   
 
 
Figure 4.12: Cell viability effect of the citric acid standard on the human fibroblast normal 
GM3348 cells. Data are expressed as the mean±S.D of three independent experiments.  
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inhibitory activity compared to other fractions. No suitable extraction solvent was available to 
extract the hydrophilic compounds from water fraction.  
Thus, reversed-phase HPLC was used to separate the compounds. The water extract was 
fractionated to three different fractions to eliminate a large number of fraction analysis and also 
to evaluate the potential loss of anticancer activity due to the synergic effect. Only one fraction 
showed a strong effect in inhibiting cell cycle re-entry up to 48 h, while the other two fractions 
exhibited a mild effect. It can be concluded that these fractions still possessed the activity; 
however, it was not strong to stop the cells from entering the S phase, which could be due to the 
concentration or synergic factor. These fractions were prepared to the initial concentration 
similar to water extract, thus the inhibitory effect of the extract was not strong to stop the cancer 
cells from re-entering into the cell cycle. It is possible for these fractions to exhibit the activity 
with the increase of the concentration. Further fractionation of the strongest fraction led to the 
isolation of one compound that was responsible for the observed cell cycle re-entry inhibitory 
activity. The compound was identified as citric acid.  
Citric acid is a weak tricarboxylic acid found majorly in citrus fruits. Citric acid also presents in 
various produced foods because citric acid is used as food additives. An adult takes 
approximately 4 g of citric acid daily via various sources including foods (Goldberg, Grass et al. 
1989). It is reported the plasma citrate levels is approximately about 19.2 µg/mL and the level is 
affected by the oral citrate load (Goldberg, Grass et al. 1989). Due to the pH of blood, citric acid 
exists mainly in citrate in blood and urine (Mycielska, Patel et al. 2009).  
Citrate has been suggested to play a role in cancer where low concentration of citrate in cancer 
cells is believed to promote cancer aggressiveness (Mycielska, Patel et al. 2009, Giskeødegård, 
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Bertilsson et al. 2013, Philippe and Hubert 2016). A metabolic profiling of prostate cancer tissue 
samples revealed citrate concentration was twice lower in high-grade cancer tissue than in low-
grade cancer tissue (Giskeødegård, Bertilsson et al. 2013). Not only that, the intracellular citrate 
in PC-3 prostate cancer cells were about 40% lower than the than normal PNT2-C2 epithelial 
cells (Mycielska, Broke-Smith et al. 2006). It was also reported that the concentration of citrate 
in peripheral zone tissue of the normal prostate was about 12000–14000 nmols/gram, which is 
relatively higher than the concentration of citrate on other tissues (250–450 nmols/gram) and 
blood plasma (100–200 nmols/gram)(Costello and Franklin 2006). 
In this study, citric acid significantly reduced cell viability of prostate cancer cells dose-
dependently at a concentration above 250 µg/mL. Previous in-vitro studies have shown that citric 
acid and citrate inhibited proliferation of different cancer lines such as A549, MCF-7, BxPC3, 
B16F10, WM983B, EC109, MSTO-211H, SKOV3, IGROV1-R10,  BGC-823 and SGC-7901 
cells at different sensitivity when tested in the concentration up to 6 mg/mL (Zhang, Varin et al. 
2009, Lu, Zhang et al. 2011, Lincet, Kafara et al. 2013, Ying, Chen et al. 2013, Chen, Lv et al. 
2017, Ren, Seth et al. 2017). Tumour growth reduction by citrate was also observed in A549 
lung cancer in-vivo mice model (Ren, Seth et al. 2017). In this study, citric acid showed 
selectivity in targeting cancer cells as citric acid showed no cell viability effect on the GM3348 
cells, while a stronger effect on PC-3 than on the RWPE-1 cells. PC-3 and RWPE-1 cells showed 
different sensitivity to citric acid treatment at a concentration above 1 mg/mL as significant 
different viability effect between these cells were observed. In one study, citrate concentration up 
to 1.54 mg/mL retained more than 75% of normal RWPE-1 prostate cells after 48 h of incubation 
(Hong, Choi et al. 2012). Citrate was also reported to have no effect on the endocytosis, lateral 
motility and adhesion of normal prostate epithelial (PNT2-C2) cells in contrast to PC-3M 
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prostate cancer cells (Mycielska, Broke-Smith et al. 2006). However, in another study, citrate 
showed no selectivity on normal and cancer lung cells at similar tested concentrations (Ren, Seth 
et al. 2017). This indicates that citric acid, like the other compounds, has different toxicity level 
on cells. It is important to mention that the culture medium was neutralized to pH 7.4 after the 
addition of citric acid in this study to ensure the pH of solution does not affect the cell growth.  
In the present study, citric acid prevented the quiescent PC-3 cells from entering S phase by 
arresting the cells at the G0/G1 phase. For proliferating cells, it was shown citric acid-induced 
cell cycle arrest at the G2/M phase and S phase on HaCaT cells (Ying, Chen et al. 2013), while 
sodium citrate arrested the gastric cancer cells at G2/M (Wang, Zhang et al. 2016). In another 
study, temporary growth retardation was observed on lung cancer MSTO-211H cells when the 
cells were exposed to citrate (Zhang, Varin et al. 2009). Not only that, administration of cisplatin 
at the end of citrate exposure caused massive apoptosis with no any cell growth recovery of 
MSTO-211H even after 14 days, which were not observed with the treatment of cisplatin or 
citrate alone (Zhang, Varin et al. 2009). Strong cytotoxicity was also observed in SKOV3 and 
IGROV1-R10 ovarian cells that were treated with ABT-737 compound after exposure to citrate 
for 24 h (Lincet, Kafara et al. 2013). In another study, the combination administration of citrate 
and cisplatin reduced tumour growth in lung cancer in-vivo model (Ren, Seth et al. 2017). These 
findings suggest the ability of citric acid to enhancing the sensitivity and efficiency of 
chemotherapy drugs.  
Citrate also was shown to induce apoptosis in different cancer including nerve, lung, esophageal, 
breast, skin, pancreas and ovary cancer (Zhang, Varin et al. 2009, Kruspig, Nilchian et al. 2012, 
Lincet, Kafara et al. 2013, Chen, Lv et al. 2017, Ren, Seth et al. 2017). However, no apoptosis 
was observed in this study when the PC-3 cells were treated with the citric acid up to 48 h. Sub-
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G1 was not found in the result of flow cytometry (data not shown), which is similar to the 
previous finding using water extract of citrus peel on the quiescent prostate cancer cells.   
Citrate was also reported to play a significant role in glycolysis and the tricarboxylic acid cycle 
as citrate is one of the main intermediates of the tricarboxylic acid cycle (Mycielska, Patel et al. 
2009). It was found the citrate suppressed glycolysis and the tricarboxylic acid cycle in-vitro and 
in-vivo on A549 tumour cells (Ren, Seth et al. 2017). Similarly, citrate was shown to decrease 
glycolysis on in-vitro and in-vivo gastric cancer cells (Wang, Zhang et al. 2016). The decreases 
in the glycolysis and the tricarboxylic acid cycle were reported due to the inhibition of 
phosphofructokinase enzyme (Kruspig, Nilchian et al. 2012, Lincet, Kafara et al. 2013). Sodium 
citrate significantly reduced selectively the phosphofructokinase-1 on the human gastric cancer 
cell line (SGC-7901) (Wang, Zhang et al. 2016). In another study, citrate suppressed 
phosphofructokinase in Ras tumours only and not in Neu driven tumours (Ren, Seth et al. 
2017). Citrate is regarded as an inhibitor of phosphofructokinase enzyme (Norberg and Siesjo 
1975) and citric acid could be an anticancer agent. 
When looking at the citrate intake safety, no significant toxicity to the internal organs of the 
animals treated with citrate was observed (Ren, Seth et al. 2017). The animals that were given 
citrate (total dose 8 g per day) by gavage or drinking water had citrate concentration at 
approximately 3 mM in plasma, which was roughly eight times than those noted in non-citrate 
treated animals (Ren, Seth et al. 2017). Not only that, two patients that were given citrate orally 
showed no health side effect and was well-tolerated (Halabe 2009, Bucay 2011). As surgery and 
radiotherapy are not preferred on elderly men as it tends to worsen health, functional food 
supplements could be an alternative option in halting risk of progression and recurrence of 
prostate cancer. Citrus peel extract that contains citric acid together with various bioactive 
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compounds has been shown to induce cell cycle re-entry inhibitory effect on quiescent prostate 
cancer cells. Combination of various bioactive compounds together with citric acid in citrus peel 
extract could mimic the synergic effect observed when a drug is administered in the presence of 
another drug or compound during cancer treatment.  
 
4.5 Conclusion 
In this study, citric acid was identified as one of the potent compounds in citrus peel extract that 
are responsible for the cell cycle re-entry inhibitory effect on prostate cancer cells. Citric acid 
showed toxic selectivity by targeting cancer cells than normal prostate cells.  A synergic effect 
was observed where the fractions showed a reduction in the strength of cell cycle inhibitory 
effect compared to water extract. Intake of citrus peel extract as a whole is suggested for 
optimum health-promoting effect.  
 
  
97 
 
5 Proteomic analysis for the identification of cell 
cycle re-entry inhibitory proteins in quiescent 
prostate cancer cells. 
 
5.1 Introduction    
Cancer cells are characterized by their uncontrolled proliferation; however, some of these cells 
cease proliferating and enter a quiescent state. These quiescent cells can remain dormant for a 
long period and eventually may result in cancer recurrence (Yeh and Ramaswamy 2015). The 
quiescent cells can re-enter the cell cycle upon the presence of growth-factor signalling 
stimulations (Olejniczak, La Rocca et al. 2013). Thus, understanding the re-entry of quiescent 
cells into the cell cycle is vital for the effective treatment of malignant cancers.  
The proteins involved in the cell cycle process have been identified and the mechanisms for 
regulating the transition of cells from quiescence to the proliferative state were elucidated in 
several studies (Malumbres and Barbacid 2001, Wang and Lin 2013, Yeh and Ramaswamy 
2015). Key factors proteins involved in cell cycle progression are cyclin‐dependent kinase 
(CDK), CDK inhibitors and cyclin (Otto and Sicinski 2017). Modulation of several proteins such 
as the DREAM complex, DYRK1B, NR2F1, Axl, Tyro3, and uPAR was also associated with 
regulation of cell quiescence. Although, various proteins have been implicated in cell cycle 
regulation, the precise mechanism of cancer relapse and cell cycle re-entry of quiescent cells is 
complex and unknown.  
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Citric acid or citrate has shown anticancer activity on multiple cancerous cell lines such as 
breast, pancreas, lung, and esophageal cancer cells (Chen, Lv et al. 2017, Mycielska, Dettmer-
Wilde et al. 2018). Previous studies have also reported that citrate and citric acid arrest gastric 
and ovarian cancer cells at G2/M phase (Lincet, Kafara et al. 2013, Wang, Zhang et al. 2016), 
and mesothelioma cells at G0/G1 phase (Zhang, Varin et al. 2009).  In this study, it was found 
that citric acid and citrate from citrus inhibited cell cycle re-entry of quiescent PC-3 cells. 
Although various mechanisms have purported for the anticancer activity of citric acid, the 
precise mode of action of citric acid in cell cycle re-entry inhibition has not yet been identified.  
Understanding the relation between cancer quiescence and metabolism may lead to the 
identification of novel biomarkers and the development of an active compound for the 
prevention of cancer. Therefore, in this chapter, it was aimed to determine the inhibition 
mechanism of citric acid on quiescent PC-3 cells. Stable-isotope labelling by amino acids in cell 
culture (SILAC) was used to compare the protein expression during the cell cycle re-entry of 
citric acid treated quiescent cells with the control. Subsequently, computational analysis was 
performed to identify critical protein differences between the treated and untreated cell 
populations. 
 
5.2 Materials and methods 
5.2.1 Chemicals and reagents 
Trypsin Protease MS Grade (90057), RPMI 1640 SILAC Protein Quantitation Kit (A33971), 
Qubit Protein Assay (Q33211), FxCycle™ PI/RNase Staining Solution (F10797), trypsin 
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(90057), dithiothreitol (R0861) were obtained from Life technologies.  Urea (U4883), thiourea 
(T8656), iodoacetamide (A3221), triethylammonium bicarbonate buffer (T7408), trifluoroacetic 
acid (T6508), formic acid (5330020050), MS grade acetonitrile (1000292500) were obtained 
from Sigma.    
 
5.2.2 Cell culture and SILAC labelling  
Bone metastasized prostate cancer cells (PC-3) obtained from American Type Culture Collection 
(Rockville, MD) were grown in RPMI-1640 SILAC culture media supplemented with 
12
C6-
(LIGHT) or 
13
C6 (HEAVY)-L-lysine RPMI containing 10% of dialyzed fetal bovine serum in a 
humidified cell incubator at 37°C in the presence of 5% CO2. The medium of both populations 
was replaced every two days and the cells were passaged routinely when the confluency reached 
80–90%. The percentage of incorporation efficacy was determined before the cells were used for 
the experiment and it was typically more than 99%.  The SILAC labelled PC-3 cells in a T25 
flask were forced to enter quiescence by contact inhibition method as described in Section 3.2.3 
(Xi, Yao et al. 2016). Briefly, after three days of contact inhibition, the HEAVY labelled cells 
were trypsinized and seeded at low density in T25 flask together HEAVY culture medium 
containing citric acid at a concentration of 700 µg/mL (neutralized with sodium hydroxide to pH 
7.4). Meanwhile, the LIGHT labelled cells were trypsinized and seeded at low density in T25 
flask together LIGHT culture medium. At the end of the treatment, the cells were trypsinized, 
washed with PBS and the dry pellet was stored at -80°C prior to sample preparation for mass 
spectrometry. Three different independent biological experiments were prepared for MS 
analysis. About 10% of each sample was fixed with 70% ethanol and subjected for cell cycle 
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analysis with a flow cytometer. 
 
5.2.3 Protein quantitation using Qubit method 
The Qubit protein assay was conducted according to the manufacturer’s protocol. Briefly, the 
Qubit working solution was prepared by diluting the Qubit® Protein Reagent 1:200 in Qubit® 
Protein Buffer. The protein standards (10 µL) or the samples (1-20 µL) were mixed with Qubit 
working solution to a final volume of 200 µL. The solution was incubated for 15 minutes at 
room temperature and the fluorescence of the dye was measured using the Qubit 2.0 fluorometer. 
Protein concentration was calculated using the formula: concentration of the sample in µg/mL = 
the value is given by the fluorometer * (200/volume of the sample used). 
 
5.2.4  Sample preparation for mass spectrometry  
The cell pellet was dissolved in 200 µL of lysis buffer containing 100 mM Tris Buffer pH 7.6, 
6M urea and 2M thiourea. The cells were homogenized with two pulses of 20 seconds using a 
tip-probe sonicator. The homogenate was centrifuged at 16,000 g for 10 mins at 4 °C and the 
supernatant was collected. One mL of -20°C cooled acetone was added to the collected 
supernatant and the solution was stored at -20°C overnight to precipitate the proteins. The 
solution was centrifuged at 16,000 g for 10 min at 4 °C and the supernatant was removed. The 
protein pellet was dissolved in 80% acetone, centrifuged and the pellet was dried with a nitrogen 
stream. The dried protein pellet was dissolved in 50 µL lysis buffer and total protein in the 
solution was quantified using the Qubit Protein Assay Kit. A 50 µg of protein from LIGHT and 
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HEAVY were combined and made up to 50 µL with lysis buffer. The proteins were reduced in 
10 mM of dithiothreitol at room temperature for 30 min and alkylated in 25 mM of 
iodoacetamide in the dark at room temperature for 30 min. The excess iodoacetamide was 
reduced with 20 mM of dithiothreitol at room temperature for 30 min. The solution was diluted 
with 50 mM triethylammonium bicarbonate buffer in the ratio of 1: 6 and digested with trypsin at 
a ratio of 1:20 (trypsin/protein, w/w) for 16 h at 37°C. The digested solution was acidified with 
trifluoroacetic acid to a final concentration of 1% (v/v).  The digested solution was centrifuged at 
16,000 g for 10 mins at 4°C and the peptides in the supernatant were loaded on Millipore peptide 
concentrator C18 ZipTip (ZTC18S096). The cartridge was washed three times with 0.1% of 
trifluoroacetic acid and the peptides were eluted with 60% of acetonitrile. The cleaned peptide 
samples were resuspended in 3% (v/v) acetonitrile and 0.1% (v/v) formic acid for LC-MS/MS 
analysis (1 μg/injection).   
 
5.2.5 LC-ESI-MS/MS 
LC-MS/MS analysis was carried out on a nanoflow Ultimate 3000 µHPLC (Dionex Corp, 
Sunnyvale, CA, USA) coupled online to a Q-Exactive™ Plus mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA) with a nanospray ionization ion source in positive mode. 
Peptides were separated using an in-house packed C18-reversed phase column (75 μm × 45 cm) 
with a linear gradient of 5–35% Buffer B over 90 min at 250 nL/min at 60°C (Buffer A = 0.1% 
(v/v) formic acid; Buffer B = 80% (v/v) acetonitrile, 0.1% (v/v) formic acid). An MS1 scan was 
acquired from 350–1550 (70000 resolution, 3e6 automatic gain control, 100 ms injection time). 
Twenty most intense precursor ions from a full MS1 scan were selected in each cycle for MS/MS 
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data-dependent acquisition with higher energy collision dissociation (HCD) fragmentation and 
detection in the Orbitrap (17500 resolution, 1e
5
 automatic gain control, 60 ms injection time, 30 
eV normalized collision energy, 1.2 m/z isolation window, 1.7e
5
 precursor intensity threshold; 
minimum charge state of 2+; dynamic exclusion of 90 s).  
 
5.2.6 Analysis of mass spectrometric data 
The raw data were processed with Proteome Discoverer 2.2 (Thermo Fisher Scientific, Bremen, 
DE). MS/MS spectra were searched using SEQUEST HT algorithm against the reviewed 
UniProt human database containing 20,373 entries (June, 2018). MS mass tolerance was set to 
10 ppm and MS/MS mass tolerance was set to 0.05 Da. Identical peptides from the different 
samples co-elute as pairs of peaks and distinguishable by the mass difference between the heavy 
and light isotope labels. The peptides were identified with up to two missed cleavages for tryptic 
peptides with oxidation (M), acetylation of the N‐terminus and SILAC modifications of lysine 
(K) as variable modifications, while carbamidomethylation (C) was used as a fixed modification. 
The peptides and proteins were validated for false discovery rates (FDR) using percolator 
algorithm Node and protein FDR validator node with a q-value threshold of 0.01. Only proteins 
that identified with high confidence, belong to master protein and contain at least one unique 
peptide were selected for further analysis. Ambiguous proteins were manually removed by 
comparing the absence/presence in three different biological replicates. 
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5.2.7 Bioinformatics analysis 
Protein-protein interactions and networks were evaluated using STRING v10 software 
(https://string-db.org/) with the confidence level of more than 0.4. Gene ontology annotation was 
obtained using PANTHER tool (http://www.pantherdb.org/). Ingenuity® Pathway Analysis 
(http://www.ingenuity.com/) was used to search the relevant pathways of these identified 
proteins.   
 
5.3 Results 
5.3.1 Cell cycle analysis of the prostate cancer cells 
Contact-inhibited prostate cancer PC-3 cells were released from quiescence phase by passaging 
the cells at low density in the presence of citric acid (neutralized with sodium hydroxide to pH of 
7.4) at IC50 concentration (0.7 mg/mL) for treated (HEAVY) cells or in phosphate buffer solution 
for control (LIGHT) cells. The IC50 of citric acid for PC-3 cells were determined in the previous 
chapter. The cells after 16 and 24 h were collected and analysed for the DNA content using BD 
FACS Canto II flow cytometer. Figure 5.1  shows an image of PC-3 cells that were incubated 
with citric acid at 16 and 24 h upon released from quiescence phase. Furthermore, the result of 
the cell cycle of PC-3 cells before and after release from quiescence phase in the presence of 
citric acid at 16 and 24 h is depicted in Figure 5.2. It was observed that when the cells were 
released from quiescence, the number of cells at the S phase for control sample at 16 and 24 h 
was increased compared to the quiescent cells. Meanwhile, a number of cells at the G2/M phase 
for control sample at 16 h was almost unchanged and an increased from 11.8% to 18.8% at 24 h 
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was observed. This effect was proportional to the decrease in the number of cells at the G1 phase 
for the control. However, for treated cells, no changes in the number of cells in each phase were 
observed at 16 and 24 h compared to quiescent cells. These cell cycle re-entry inhibition results 
are in broad agreement with the results from Chapter 4. 
 
Control at 16 h 
 
Treated at 16 h 
 
Control at 24 h 
 
Treated at 24 h 
Figure 5.1: Image of PC-3 cells treated with citric acid standard (pH 7.4) at 16 and 24 h upon 
release from quiescence were assessed by Nikon Eclipse TS100 inverted microscope.  
 
500 µm 500 µm 
500 µm 500 µm 
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Figure 5.2: Cell cycle profile of PC-3 cells treated with citric acid standard upon release from 
quiescence.  Quiescent cells are PC-3 cells after contact inhibition for 3 days. Data are expressed 
as the mean of two independent biological experiments (n=2).   
 
5.3.2 Proteomic analysis of the prostate cancer cells 
A quantitative proteomic analysis was conducted based on a SILAC labelling as illustrated in 
Figure 5.3 to identify the changes in the protein expression during cell cycle re-entry of quiescent 
prostate cancer cells (PC-3). Three biological samples were analysed by LC-MS/MS that 
included control and citric acid treated PC-3 cells. 
 
Quiescent Control Treated Control Treated
0 h 16 h 24 h
G0/G1 87.8 86.05 86.75 77.6 86.65
S 1.25 2.2 0.65 3.7 0.9
G2/M 10.95 11.85 11.3 18.8 12.4
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Figure 5.3: Schematic representation of steps undertake for SILAC labelling and proteomic 
analysis. The LIGHT and HEAVY SILAC labelled proliferating PC-3 cells were contact 
inhibited for three days before passaged at low density in the presence of phosphate buffer 
solution (control) and citric acid standard (treated). At 16 and 24 h, total cell lysate proteins were 
collected, mixed and digested with trypsin before analysed with liquid chromatography based 
tandem mass spectrometry (LC-MS/MS). The ratio of HEAVY vs. LIGHT intensity of peptide 
MS spectrum was used for the fold change calculation. The ratios were subjected to post-analysis 
interpretation.  
 
5.3.3 Identification of differentially expressed proteins by SILAC labelled proteomics 
Peptides obtained from the digested proteins of PC-3 cells were analysed using LC-MS/MS. 
Figure 5.4 shows the total ion chromatogram for samples at 0, 16 and 24 h. The chromatograms 
were almost similar in intensity and elution pattern. The raw spectral data were interpreted using 
Proteome Discoverer 2.2 by searching against reviewed Homo sapiens UniProt database at 1% 
FDR at both peptide and protein levels. The samples of MS/MS spectra of a peptide fragmented 
from the FN3KRP protein are presented in Figure 5.5 (a). In the MS/MS analysis, b and y ions of 
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various peptides were detected and matched in Proteome discoverer software analysis. A SILAC 
quantitation method was used to determine the abundance of protein expression in control and 
treated PC-3 cells. Figure 5.5 (b) shows the intensity of LIGHT and HEAVY labelled doubly-
charged peptide for the FN3KRP protein with m/z value differ by 3 Da. 
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Figure 5.4: Examples of total ion chromatogram of digested proteins of whole prostate cancer PC-3 cells at a different time. 
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Figure 5.5: MS/MS spectra of RMFEGEMASLTAILk peptide from FN3KRP protein (a) and 
MS spectra for light (control) and heavy (treated) labelled lysine corresponding to the 
RMFEGEMASLTAILk doubly-charged peptide ion separated by the specific 3 Da delta mass 
(b). 
 
 
3 Da 
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a) 
Light 
Heavy 
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5.3.4 Differentially expressed proteins in cell cycle re-entry of PC-3 cells 
The processed raw spectral data revealed an average of about 3000 proteins in each sample. The 
protein lists were filtered using the following parameters: protein FDR confidence (high), 
abundance LIGHT and HEAVY (any value), unique peptides (equal or more than 1), master 
protein (master), and contaminant (not). For each sample, nearly 1400 proteins were quantified 
with high confidence and their log2 (HEAVY/LIGHT) ratio are shown in Figure 5.6. The log2 
ratio distribution is shown in Figure 5.6 and most of the proteins were within one-fold log2. 
There were more proteins with the larger ratio at 24 h compared to 0 and 16 h as indicated by the 
distribution plots. The high number of proteins within one-fold log2 shows that the proteins from 
control and treated samples were mixed at an equal amount. The proteins that were differentially 
expressed by at-least one-fold and found at least once from three biological experiments at 16 h 
and 24 h are listed in Table 5.1 and Table 5.2.  
Number of differentially expressed proteins at least by one-fold at 16 and 24 h were 68 proteins 
and 62 proteins, respectively. Among these proteins, 17 proteins were found at both 16 and 24 h 
(Figure 5.6), which were ALDH3A1, S100A2, SYNGR2, PFKP, SUCLA2, MAPK1, SUMO1, 
KPNA2, NHP2, AHSG, IGF2BP3, PCBP3, LUC7L2, NAA10, FN3KRP, ACADM and HBA1. 
Among the proteins listed in Figure 5.6, S100A2, H3F3A, CDK1, NEDD8, MCM4, JPT1, 
AKT1, IDE and LMO7 are associated with cell cycle and cell cycle-related signalling.  
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Figure 5.6: Plots (right) and histogram graph (left) of normalized log2 SILAC ratios against 
high confidence identified proteins sorted by their ratios in ascending order at 16 and 24 h for 
one biological experiment.   
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Table 5.1: List of proteins that were differentially expressed at least one-fold at 16 h in PC-3 
cells. 
Protein 
accession 
GENE 
name 
Protein name  Coverag
e [%] 
Unique 
Peptides 
log2(H/L) 
P02765 AHSG Alpha-2-HS-glycoprotein 7 3 -3.90 
P29034 S100A2 Protein S100-A2  28 4 -3.31 
P84243 H3F3A Histone H3.3 65 2 -3.27 
P69905 HBA1 Hemoglobin subunit alpha 35 5 -3.06 
O60684 KPNA6 Importin subunit alpha-7 14 2 -2.98 
P27694 RPA1 Replication protein A 70 kDa DNA-binding 
subunit 
6 3 -2.71 
O60220 TIMM8A Mitochondrial import inner membrane 
translocase subunit Tim8 A 
27 2 -2.56 
P40616 ARL1 ADP-ribosylation factor-like protein 1 17 2 -2.46 
Q9NNW7 TXNRD2 Thioredoxin reductase 2, mitochondrial 10 2 -2.37 
Q9BZZ5 API5 Apoptosis inhibitor 5 7 4 -1.93 
Q8N1G4 LRRC47 Leucine-rich repeat-containing protein 47 15 7 -1.86 
P61006 RAB8A Ras-related protein Rab-8A 28 2 -1.79 
Q01813 PFKP ATP-dependent 6-phosphofructokinase, 
platelet type  
16 5 -1.79 
Q9P2R7 SUCLA2 Succinate--CoA ligase [ADP-forming] 
subunit beta, mitochondrial 
25 7 -1.74 
O75844 ZMPSTE24 CAAX prenyl protease 1 homolog 8 2 -1.70 
O60888 CUTA Protein CutA 16 2 -1.60 
P62495 ETF1 Eukaryotic peptide chain release factor 
subunit 1 
7 3 -1.55 
P42704 LRPPRC Leucine-rich PPR motif-containing protein, 
mitochondrial 
44 48 -1.51 
P35237 SERPINB6 Serpin B6 43 13 -1.45 
O43237 DYNC1LI2 Cytoplasmic dynein 1 light intermediate 
chain 2 
9 1 -1.40 
P61160 ACTR2 Actin-related protein 2 37 1 -1.34 
P11310 ACADM Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
19 6 -1.31 
P33991 MCM4 DNA replication licensing factor MCM4 6 3 -1.30 
O43760 SYNGR2 Synaptogyrin-2 8 2 -1.27 
P51397 DAP Death-associated protein 1 35 2 -1.24 
O14786 NRP1 Neuropilin-1 9 5 -1.22 
Q9UK76 JPT1 Jupiter microtubule-associated homolog 1 26 2 -1.22^ 
P53634 CTSC Dipeptidyl peptidase 1 16 5 -1.21 
P31749 AKT1 RAC-alpha serine/threonine-protein kinase 4 1 -1.16 
Q9Y3A5 SBDS Ribosome maturation protein SBDS 11 3 -1.16 
P52292 KPNA2 Importin subunit alpha-1  10.5 3.5 -1.15^ 
P20962 PTMS Parathymosin 23 2 -1.14 
Q14554 PDIA5 Protein disulfide-isomerase A5 5 1 -1.14 
P13796 LCP1 Plastin-2 33 13 -1.11 
P21980 TGM2 Protein-glutamine gamma-
glutamyltransferase 2 
41 19 -1.10 
P62861 FAU 40S ribosomal protein S30 19 2 -1.09 
Q6DD88 ATL3 Atlastin-3 20 7 -1.08 
P62136 PPP1CA Serine/threonine-protein phosphatase PP1-
alpha catalytic subunit 
52 2 -1.07 
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Protein 
accession 
GENE 
name 
Protein name  Coverag
e [%] 
Unique 
Peptides 
log2(H/L) 
P12110 COL6A2 Collagen alpha-2(VI) chain 3 3 -1.06 
Q9H3P7 ACBD3 Golgi resident protein GCP60 5 2 -1.06 
P41227 NAA10 N-alpha-acetyltransferase 10  19 3 -1.04 
P62854 RPS26 40S ribosomal protein S26 40 1 -1.04 
P35222 CTNNB1 Catenin beta-1 13 7 -1.04 
P62244 RPS15A 40S ribosomal protein S15a 44 7 -1.03 
P17096 HMGA1 High mobility group protein HMG-I/HMG-
Y 
40 2 1.02 
P14735 IDE Insulin-degrading enzyme 2 2 1.02 
Q9NX24 NHP2 H/ACA ribonucleoprotein complex subunit 
2  
13 1 1.02 
P28482 MAPK1 Mitogen-activated protein kinase 1 34 7 1.03 
O14602 EIF1AY Eukaryotic translation initiation factor 1A, 
Y-chromosomal 
15 0 1.08 
P16402 HIST1H1D Histone H1.3 17 8 1.09 
P00414 MT-CO3 Cytochrome c oxidase subunit 3 5 1 1.12 
O95834 EML2 Echinoderm microtubule-associated protein-
like 2 
7 3 1.20 
P08174 CD55 Complement decay-accelerating factor 4 2 1.24 
P31153 MAT2A S-adenosylmethionine synthase isoform 
type-2 
30 2 1.25 
P35914 HMGCL Hydroxymethylglutaryl-CoA lyase, 
mitochondrial 
16.5 3 1.25^ 
Q96I24 FUBP3 Far upstream element-binding protein 3 24 10 1.29 
Q15843 NEDD8 NEDD8 41 3 1.35 
P30838 ALDH3A1 Aldehyde dehydrogenase, dimeric NADP-
preferring 
11 3 1.51 
Q14257 RCN2 Reticulocalbin-2 6 1 1.54 
O00244 ATOX1 Copper transport protein ATOX1 47 3 1.56 
O14548 COX7A2L Cytochrome c oxidase subunit 7A-related 
protein, mitochondrial 
29 1 1.63 
P57721 PCBP3 Poly(rC)-binding protein 3  18 1 1.66 
Q99627 COPS8 COP9 signalosome complex subunit 8 30 4 2.16 
O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-binding 
protein 3 
4 1 2.88 
Q9Y383 LUC7L2 Putative RNA-binding protein Luc7-like 2 11 5 3.06 
P52907 CAPZA1 F-actin-capping protein subunit alpha-1 69 8 3.13 
P63165 SUMO1 Small ubiquitin-related modifier 1  28 1 4.33 
Q9HA64 FN3KRP Ketosamine-3-kinase  16 3 5.10 
^ Found in two samples, log2 H/L means the ratio of treated to control 
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Table 5.2: List of proteins that were differentially expressed at least one-fold at 24 h in PC-3 
cells. 
Accession GENE name Protein name  Coverage 
[%] 
Unique 
Peptides 
log2(H/L) 
P02765 AHSG Alpha-2-HS-glycoprotein 7 3 -3.47^ 
Q32MZ4 LRRFIP1 Leucine-rich repeat flightless-
interacting protein 1  
2 1 -3.47 
P69905 HBA1 Hemoglobin subunit alpha 35 4 -2.49 
Q9NYY8 FASTKD2 FAST kinase domain-containing protein 
2, mitochondrial 
2 1 -2.45 
Q9P2R7 SUCLA2 Succinate--CoA ligase [ADP-forming] 
subunit beta, mitochondrial 
16 5 -2.40^ 
P04183 TK1 Thymidine kinase, cytosolic  6 1 -2.36 
P06493 CDK1 Cyclin-dependent kinase 1  21 6 -2.22 
Q01813 PFKP ATP-dependent 6-phosphofructokinase, 
platelet type  
15 6 -2.11 
Q9UHD1 CHORDC1 Cysteine and histidine-rich domain-
containing protein 1  
5 1 -2.01 
Q9Y5B9 SUPT16H FACT complex subunit SPT16  5 5 -1.93 
P41227 NAA10 N-alpha-acetyltransferase 10  14 2 -1.88 
A6NHR9 SMCHD1 Structural maintenance of chromosomes 
flexible hinge domain-containing 
protein 1  
1 2 -1.65 
Q13409 DYNC1I2 Cytoplasmic dynein 1 intermediate 
chain 2 
13 4 -1.60 
P23921 RRM1 Ribonucleoside-diphosphate reductase 
large subunit 
2 1 -1.55 
P52292 KPNA2 Importin subunit alpha-1  11 4 -1.52^ 
O75494 SRSF10 Serine/arginine-rich splicing factor 10 19 3 -1.49 
P63220 RPS21 40S ribosomal protein S21 (Small 
ribosomal subunit protein eS21) 
65 5 -1.49 
O15460 P4HA2 Prolyl 4-hydroxylase subunit alpha-2  6 2 -1.42 
P29034 S100A2 Protein S100-A2  27 3 -1.41 
O43760 SYNGR2 Synaptogyrin-2 8 2 -1.38 
P29218 IMPA1 Inositol monophosphatase 1 30 6 -1.35 
P82673 MRPS35 28S ribosomal protein S35, 
mitochondrial 
8 1 -1.34 
Q05682 CALD1 Caldesmon 4 2 -1.33 
P15924 DSP Desmoplakin  1 2 -1.33 
P67936 TPM4 Tropomyosin alpha-4 chain  31 1 -1.23^ 
P11310 ACADM Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
22 7 -1.19 
O15355 PPM1G Protein phosphatase 1G  5 2 -1.16 
Q08211 DHX9 ATP-dependent RNA helicase A  19 21 -1.12 
Q96FW1 OTUB1 Ubiquitin thioesterase OTUB1  29 6 -1.12 
O95340 PAPSS2 Bifunctional 3'-phosphoadenosine 5'-
phosphosulfate synthase 2  
4 2 -1.10 
Q96KP4 CNDP2 Cytosolic non-specific dipeptidase 6 2 -1.08 
O75533 SF3B1 Splicing factor 3B subunit 1 7 4 -1.08 
P17844 DDX5 Probable ATP-dependent RNA helicase 
DDX5  
40 13 -1.05 
P28288 ABCD3 ATP-binding cassette sub-family D 9 5 -1.03 
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Accession GENE name Protein name  Coverage 
[%] 
Unique 
Peptides 
log2(H/L) 
member 3 
P61289 PSME3 Proteasome activator complex subunit 3 23 5 1.00 
P31483 TIA1 Nucleolysin TIA-1 isoform p40 6 2 1.00 
O00116 AGPS Alkyldihydroxyacetonephosphate 
synthase, peroxisomal  
12 6 1.07 
Q9UBS4 DNAJB11 DnaJ homolog subfamily B member 11 21 5 1.08 
O60841 EIF5B Eukaryotic translation initiation factor 
5B 
5 5 1.13 
Q15287 RNPS1 RNA-binding protein with serine-rich 
domain 1  
8 3 1.17 
P57721 PCBP3 Poly(rC)-binding protein 3  19 1 1.21 
Q9H444 CHMP4B Charged multivesicular body protein 4b  19 5 1.31 
Q8WWI1 LMO7  LIM domain only protein 7 10 14 1.38 
P63165 SUMO1 Small ubiquitin-related modifier 1  36 4 1.40 
P30838 ALDH3A1 Aldehyde dehydrogenase, dimeric 
NADP-preferring 
8 2 1.41 
P28482 MAPK1 Mitogen-activated protein kinase 1 34 5 1.42 
Q08722 CD47 Leukocyte surface antigen CD47  3 1 1.45 
P61026 RAB10 Ras-related protein Rab-10 24 3 1.57 
O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-
binding protein 3 
5 1 1.58 
P20591 MX1 Interferon-induced GTP-binding protein 
Mx1 
7 3 1.62 
P62314 SNRPD1 Small nuclear ribonucleoprotein Sm D1 20 2 1.64 
Q9NX24 NHP2 H/ACA ribonucleoprotein complex 
subunit 2  
13 1 1.87 
O60869 EDF1 Endothelial differentiation-related 
factor 1  
27 3 1.88 
Q9NR50 EIF2B3 Translation initiation factor eIF-2B 
subunit gamma 
7 3 1.89 
Q96CM8 ACSF2 Acyl-CoA synthetase family member 2, 
mitochondrial  
11 5 2.08 
Q8TD19 NEK9 Serine/threonine-protein kinase Nek9  1 1 2.18 
Q13464 ROCK1 Rho-associated protein kinase 1  2 1 2.36 
Q6UW68 TMEM205 Transmembrane protein 205 17 2 2.76 
Q9HA64 FN3KRP Ketosamine-3-kinase  11 2.5 3.26^ 
Q08378 GOLGA3 Golgin subfamily A member 3  3 3 3.42 
Q9Y383 LUC7L2 Putative RNA-binding protein Luc7-
like 2 
13 5 3.68 
Q13596 SNX1 Sorting nexin-1 6 2 6.56 
^ Found in two samples    
log2 H/L means the ratio of treated to control 
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Figure 5.7: Venn-diagram showing the differently expressed proteins at least one-fold at 16 h 
and 24 h.  
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5.3.5 Bioinformatics analysis 
To identify the biological effect induced by the citric acid on the cell cycle re-entry inhibitory 
effect, the analyses were focused on the regulated pathways rather than the fold change of the 
protein expression.  
 
5.3.6 Protein-protein interaction network 
STRING database was used to identify the protein-protein interactions and associations of co-
expressed or co-regulated proteins among the differentially expressed proteins. STRING predicts 
these interactions based on neighbourhood, gene fusion products, homology and similarity of co-
expression patterning, experiments, databases, and text mining.  
The predicted protein-protein interactions of significantly expressed proteins at 16 and 24 h are 
shown in Figure 5.8. A large proportion of proteins did not show any link at the chosen 
confidence level (STRING score=0.4) at 16 and 24 h. A strong potential interaction was found 
involving NEDD8, SUMO1, FAU, NHP2, RPS23, RPS15A, ETF1 and EIF1AY proteins at 16 h, 
while SRSF100, DDX5, RNPS1, SNRPD1, SEF3B1, DHX9, RPS21, NHP2 and EIF5B were 
predicted at 24 h. The two clusters found at 16 and 24 h were involved in protein synthesis and 
cell growth.  
AKT1 and CDK1 were revealed as the major hub proteins that tentatively interacted with many 
proteins at 16 h and 24 h, respectively. AKT1 is involved in many processes such as metabolism, 
proliferation, cell survival, growth and angiogenesis. CDK1 promotes the G2-M transition and 
also regulates the G1 progression and G1-S transition (The UniProt Consortium 2017). 
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Meanwhile, no biological processes were predicted at 16 h by the STRING database. In contrast, 
cellular metabolic process, mRNA splicing, cellular macromolecule metabolic process, 
macromolecule metabolic process and regulation of mRNA splicing were the predicted 
biological processes at 24 h.  
A number of notable protein-protein interactions were observed at 16 h and 24 h time points. At 
16 h, an inhibiting interaction was observed between MAPK1 and AKT1, and a post-
translational modification was observed between AKT1 and CTNNB1. Meanwhile, at 24 h, two 
post-translational modifications between CDK1 and NEK9, MAPK1, CALD1 and TK1, while 
another one with MAPK1 with ROCK1 and CALD1 were observed.  
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Figure 5.8: Predicted protein-protein interactions for significantly regulated proteins in citric 
acid treated PC-3 cells by STRING at 16 (a) and 24 (b) h.  
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5.3.7 Classification of Differentially Expressed Proteins 
Gene ontology (GO) analysis using PANTHER was used to identify the biological processes 
significantly affected by citric acid treatment in PC-3 cells. The identified proteins were mainly 
involved in cellular processes, metabolic processes, and cellular component organization at 16 
and 24 h as shown in Figure 5.9. The number of proteins involved in response to stimulus and 
development process decreased at 24 h compared to 16 h, while the other biological processes 
were almost similar. A cellular process involves any process that is carried out at the cellular 
level including cell communication among the cells. Meanwhile, metabolic processes involve the 
chemical reactions and pathways, including anabolism and catabolism, by which living 
organisms transform chemical substances including macromolecular processes such as DNA 
repair and replication, and protein synthesis and degradation. 
 
Figure 5.9: Gene ontology of regulated proteins classified according to biological processes.  1: 
cellular component organization or biogenesis, 2: cellular process, 3: localization, 4: biological 
regulation, 5: response to the stimulus, 6: developmental process, 7: multicellular organismal 
process, 8: metabolic process and 9: immune system process. 
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5.3.8 Identification of regulated canonical pathways  
Ingenuity Pathway Analysis (IPA) was used to identify canonical pathways from the identified 
proteins in this study. Canonical pathways are the established pathways at the cellular level 
based on the collective evidence from various experimental findings. IPA predicts the possible 
pathways that could occur in the cells based on the identified proteins with their respective fold 
changes. It was found that for most of the quantified proteins, the log2 (H/L) ratio was below ± 
1. Therefore, IPA was used to obtain a holistic view of changes involved in the cell cycle re-
entry process, focusing on all identified proteins with log2 (>±0.2). These data are shown in 
Figure 5.10. 
Theoretically, the 0 h samples are expected to have an activation score near 0 and coded with 
white colour as the ratios of heavy and light proteins were supposedly near to 1. However, some 
of the predicted canonical pathways of samples at 0 h have activation score not equal to 0 due to 
the presence of several proteins with abundance (H/L) ratio not equal to 1. The orange coloured 
box indicates the signalling pathway is activated, while the blue coloured box indicates the 
signalling pathway is suppressed in the sample. The intensity of the colour is dependent on the 
number of proteins identified and the magnitude of fold changes in the signalling pathway.  
IPA results suggest that citric acid may exert its cell cycle inhibitory effect in PC-3 cells via 
multiple canonical pathways. The prominent pathway was EIF2 signalling pathway, which was 
suppressed in citric acid treated cells. mTOR signalling, ERK/MAPK signalling, PI3k/AKT 
signalling, VEGF signalling, and regulation of eIF4 and p70S6K were suppressed in citric acid 
treated cells. Meanwhile, RhoGDI signalling, PTEN signalling, AMPK signalling and HIPPO 
signalling were activated in citric acid treated cells. Although sumoylation was activated at 16 
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and 24 h, it was less activated compared to 0 h. This observation is in accordance with the 
predicted molecular changes. As the cells enter the cell cycle, they require various cell cycle 
activation signalling pathways and formation of a range of metabolic compounds for cell growth.   
Figure 5.11 shows the protein identified in the citric acid treated PC-3 cells for the ERK/MAPK 
and PI3k/AKT canonical pathways. The expressions of these proteins were suppressed in citric 
acid treated PC-3 cells.  
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Figure 5.10: Regulated canonical pathways in cell cycle inhibited PC-3 cells were predicted by 
IPA analysis. Proteins are grouped by Canonical Pathways prioritized by hierarchical clustering, 
and z-scores are shown as heat maps. Greater intensity in orange colour indicates higher 
activation, while greater intensity in blue colour indicates higher suppression.           
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Figure 5.11: Proteins found in PI3K/AKT (a) and ERK/MAPK (b) canonical pathways predicted 
by IPA.  Proteins labelled with grey means found in experiment, red means up-regulated and 
green means down-regulated in citric acid treated PC-3 cells.      
a. 
b. 
a. 
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5.4 Discussion   
It has been reported that citric acid or citrate exhibited anticancer activity by affecting cancer cell 
metabolism, inducing tumour cell differentiation, activating the immune response and apoptosis 
in-vitro in multiple cell types (Ren, Seth et al. 2017, Mycielska, Dettmer-Wilde et al. 2018). 
However, there is little or no information available for cell cycle re-entry inhibitory effect of 
citric acid on cancer cells. This study was sought to identify the difference in the protein 
expression between the citric acid treated cells and control using a SILAC-based proteomic 
approach. The experimental result highlighted the differences in gene ontology as well as 
specific candidate factors that play a role for the citric acid response in inhibiting quiescence PC-
3 cells from re-entering the cell cycle. 
The PI3K/AKT and ERK/MAPK signalling pathways are known to be key regulators of cancer 
cell dormancy (Yeh and Ramaswamy 2015) and both were predicted to be modulated by citric 
acid in this study. AKT and MAPK1 were identified at 16 h, implying the significance of both 
pathways in inducing the cells into the cell cycle. It has been shown that the activation of 
PI3K/AKT signalling pathway is negatively controlled by PTEN (Georgescu 2010). In the 
present study, the IPA result also showed that PTEN signalling was activated in citric acid 
treated PC-3 cells in parallel with suppression of ERK/MAPK and PI3K/AKT signalling. 
Moreover, these findings align with a prior report that showed citrate inhibited IGF-1R, 
phosphorylated AKT, activated PTEN and increased expression of p-eIF2a on proliferating 
cancer cells (Mycielska, Dettmer-Wilde et al. 2018).  
Moreover, the PI3K/AKT and ERK/MAPK signalling pathways are also highly responsive to 
mitogenic factors, which can similarly lead to the metabolic activation of quiescent cells, and 
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their re-entry into the cell cycle (Otto and Sicinski 2017). A study suggested that the metabolic 
activity of the cells determines whether the cell needs to proliferate or exit the cell cycle (Duan 
and Pagano 2011). In the present study, succinate—CoA ligase and ATP-dependent 6-
phosphofructokinase were the two proteins down-regulated in citric acid treated PC-3 cells and 
these proteins are involved in cellular metabolism. Citrate was reported previously to suppress 
glycolysis and the tricarboxylic acid cycle both in-vitro and in-vivo cancer cells by inhibiting 
phosphofructokinase enzyme (Ren, Seth et al. 2017). It was hypothesised that high citric acid in 
the culture medium could inhibit cell cycle re-entry of quiescence PC-3 cells by suppressing the 
glycolysis and the tricarboxylic acid cycle. This is parallel with findings of a study where an 
axolotl oocyte extract negatively regulated the cellular metabolism of breast cancer cells in order 
to maintain the quiescency (Saad, Alberio et al. 2018). Cancer cells use glycolysis as a primary 
way to produce energy, and suppression of glycolysis could inhibit cancer cell growth and 
induce apoptosis (Vander Heiden, Cantley et al. 2009).  
The regulated proteins were sorted by fold change to identify proteins that could maintain the 
cells in quiescence. Among the significantly regulated proteins identified in this study, CDK1, 
S100A2, JPT1, AKT1, NEDD8, MAPK1 and LMO7 were associated with cell cycle and growth 
signalling. Knockdown of JPT1 was shown to suppress growth rate of PC-3 cells by modulating 
negatively AKT-mediated GSK3B signalling and also resulted in prolongation of the G1 phase 
in the cell cycle (Varisli, Gonen-Korkmaz et al. 2011). Meanwhile, S100A2 was found in a 
higher level in normal prostate cells compared to null in prostate cancer cells, indicating the key 
role of loss of this protein during the progression of prostate cancer in humans (Gupta, Hussain 
et al. 2003). SNX1 was another overexpressed protein in citric acid treated PC-3 cells and this 
protein was reported as a tumour suppressor in gastric cancer (Zhan, Zhang et al. 2018). 
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Verification of these proteins, for example by knocking out the protein in the cells, could reveal 
the possible cell cycle re-entry inhibitory activity.    
Although this study was limited with the identification of proteins involved in the re-entry of 
quiescence PC-3 cells, it still shed light on the high likely mechanisms that occurred in the citric 
acid treated cells population. Moreover, this study also provided a screened list of proteins 
involved in the cell cycle re-entry of quiescent PC-3 cells that can be validated in future studies. 
In the current study, the cells were labelled with heavy lysine and the experimental results 
showed that a large fraction of identified peptides had no lysine amino acid on the peptide 
chains. By labelling the proteins with both heavy lysine and heavy arginine, a number of proteins 
with high accuracy and confidence can be increased.  
  
5.5 Conclusion 
Suppressing cancer cell progression by modulating metabolic pathways is a current emerging 
area of cancer research and it has been proven effective in cancer treatment. Citric acid is one of 
the non-toxic and promising compounds for targeting cancer during metabolism. This study 
showed that the citric acid most likely inhibited quiescent PC-3 cells from re-entering cell cycle 
by suppressing PI3K/AKT and ERK/MAPK signalling pathways and activating PTEN signalling 
pathway. Modulations of these signalling pathways by any compounds or proteins are able to 
prevent the re-entry of quiescent cancer cells and thus potential to reduce the risk of cancer 
recurrence.    
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6 Conclusions and recommendations 
6.1 Major findings and significance of results 
Quiescent cancer cells have been regarded as one of the factors for cancer recurrence. Diet 
enriched with anticancer bioactive compounds could be a great strategy for cancer recurrence 
intervention by halting the cell cycle re-entry of quiescent cancer cells. Citrus peel has been 
shown to have anticancer activity on different cancer lines on both in-vitro and in-vivo models in 
the last two decades; however, the citrus peel inhibitory effect on cell cycle re-entry of quiescent 
cells was not reported previously. Thus, the effect of citrus peel extract and it constitutes on cell 
cycle re-entry of quiescent prostate cancer (PC-3 and LNCaP) cells was evaluated using an 
established in-vitro model of prostate cancer quiescent cells.  
This PhD thesis integrates three objectives dedicated to evaluating the possibility to use citrus 
peel in preventing prostate cancer recurrence. The first objective was focused on the evaluation 
of citrus peel extract in inhibiting the cell cycle re-entry of quiescent prostate cancer. Thus, a 
new experimental design to mimic the cancer recurrence was used in this study. For extract 
preparation, two different solvents were used, water and hexane: ethyl acetate solvent, to extract 
a range of bioactive compounds from citrus peel. Although both water and hexane extract 
reduced cell viability of prostate cancer cells, only water extract was capable in preventing the 
cells from re-entering the cell cycle. Water extract strongly inhibited the quiescent cancer cells 
that were mainly in the G0/G1 phase from entering cell cycle or S phase without causing 
apoptosis. Not only that, the extract showed selectivity in targeting cancer cells as lower toxicity 
was observed on normal human fibroblast cells compared to prostate cancer cells. The inability 
of hesperidin and naringin to inhibit the cell cycle re-entry of quiescent prostate cells suggested 
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that the major compounds present in the extract are not necessarily responsible for the observed 
effect and highlights the importance of non-predominant compounds in the extract.  
As identifying the responsible compounds for the observed biological effect could be meaningful 
in different aspects, the second objective was focused on isolation and identification of bioactive 
compounds from the water extract. Flavonoids are the major compounds in citrus and it has been 
shown that these compounds arrest a variety of different cancer lines at G0/G1 or G2/M phases. 
However, in this study, it was shown that naringin and hesperidin were not responsible for the 
observed cell cycle inhibitory effect. Thus, chromatography technique was used to screen the 
potent compounds from a range of natural compounds present in the extract. Citric acid was 
identified as one of the compounds in the water extract of citrus peel that was responsible for the 
observed cell cycle re-entry inhibitory effect. Moreover, citric acid showed toxic selectivity on 
targeting cancer cells than normal prostate cells. It was noticed that the strength of biological 
activity reduced when the extract was fractionated, which indicates the synergic effect of various 
compounds. These results further suggested that citric acid being the potent cell cycle re-entry 
inhibitor in the extract and exhibits greater cell cycle re-entry inhibitory effect in the presence of 
other bioactive compounds. Moreover, cancer recurrence does not occur via one mechanism, 
thus the presence of multiple compounds as a whole extract is required for modulation of 
multiple mechanisms related to cancer recurrence prevention.   
With the identification of the compound responsible for the cell cycle inhibitory effect, the third 
aim was to determine the possible mechanisms involved at the cellular level that trigger the 
quiescent cells to re-enter the cell cycle. Knowledge on the transition of quiescent cells to 
proliferating cells by entering into cell cycle is crucial for cancer treatment. Thus, stable isotope 
labelling using amino acids in cell culture-based proteomic experiment coupled with mass 
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spectrometric was used to determine the changes in the protein expression in the PC-3 cells when 
the cells were released from the quiescence. The results showed the citrate most likely inhibited 
PC-3 cells from entering cell cycle mainly by suppressing PI3K/AKT and ERK/MAPK 
signalling pathways and activating PTEN pathway through regulation of a number of key 
functional proteins.   
In conclusion, this study showed that citrus peel extract could arrest the quiescent prostate cancer 
and thus potential in preventing cancer recurrence. Moreover, citric acid was identified as a 
promising compound with low toxicity and a powerful inhibitory effect on the cell cycle re-entry 
of quiescent prostate cancer cells. This low toxicity and selectivity of citric acid justify further 
investigations for the potential of citric acid as a compound with chemo-preventive and 
therapeutic. Citrus peel extract that contains a range of bioactive compounds including citric acid 
can be converted into high-value nutraceutical products with the aim to prevent recurrence of 
prostate cancer in patients.   
 
6.2 Future work 
The outcomes of this study broaden the understanding of the use of citrus peel for prostate cancer 
recurrence prevention. However, more studies are needed for this research. Although citric acid 
was identified as a potent anticancer compound with cell cycle re-entry inhibitory activity in this 
study, there are potential for the presence of other compounds in the extract with a similar 
biological effect. The other bioactive compounds were not able to identify due to the low 
concentration of the compound in the extract. It is possible for these compounds to be identified 
if the concentration of fraction or extract is increased.  
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Hexane extract showed a very strong cell toxicity effect at a low concentration on the prostate 
cancer cells in this study. It is predicted that few compounds could contribute to this toxicity. It 
is also observed that the hexane extract contained very non-polar compounds, which are difficult 
to be eluted out from the C18 HPLC column. It will be interesting to identify these compounds 
and their likely effect on the cancer cells. Not only that, the non-polar compounds in citrus peel 
extract are insoluble in water, therefore it may be interesting to look at the bioavailability and 
ways to increase their absorption into the body. 
Moreover, with the identified potential pathways that initiate the cell cycle re-entry, it is 
important to validate the protein to ensure the accuracy of acquired data. It is also recommended 
to conduct an in-vivo study using mice model to confirm the potency of these active compounds 
and strengthen the hypothesis of this study. It is still unclear whether the intake of synthetic citric 
acid will exhibit similar cell cycle inhibitory effect as the citrus peel extract. An in-vivo 
experiment to compare the difference between citric acid and citrus peel extract containing citric 
acid can reveal the benefits of the natural extract. Moreover, a citrus peel powder or solution can 
be prepared by having the potent compounds and its stability and efficacy should be evaluated. It 
is crucial to evaluate the stability of extract or powder at different conditions as degradation of 
the certain bioactive compound will reduce the biological effect.  
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